

Article

Gold(I)-Catalyzed Cascade Cyclization of Anilines with Diynes: Controllable Formation of Eight-Membered Ring-Fused Indoles and Propellane-Type Indolines

Ayuta Yamaguchi, Shinsuke Inuki, Yusuke Tokimizu, Shinya Oishi, and Hiroaki Ohno

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b03256 • Publication Date (Web): 08 Jan 2020

Downloaded from pubs.acs.org on January 8, 2020


Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Gold(I)-Catalyzed Cascade Cyclization of Anilines with Diynes: Controllable Formation of Eight-Membered Ring-Fused Indoles and Propellane-Type Indolines

Ayuta Yamaguchi, Shinsuke Inuki*, Yusuke Tokimizu, Shinya Oishi, and Hiroaki Ohno*

Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan



Abstract: Heterocycle-fused indoles or indolines are distributed widely in a variety of natural products, bioactive agents and pharmaceuticals. Herein, we describe the development of gold-catalyzed cascade reactions of anilines with diynes to form eight-membered ring-fused indoles and propellane-type indolines, both of which proceed through an intramolecular *5-endo-dig* hydroamination followed by an *8-endo-dig* cycloisomerization. Controllable formation of eight-membered ring-fused indoles and propellane-type indolines was achieved through selection of the ligands and/or solvents. Protic solvents such as alcohols or IPr ligands favored the formation of


1
2
3
4
5
6 eight-membered ring-fused indoles, whereas the use of Buchwald's type ligands and/or non-polar
7
8 solvents gave propellane-type indoline predominantly. This reaction provides rapid access to two
9
10 types of fused nitrogen heterocycles from simple aniline derivatives.
11
12

13 14 INTRODUCTION

15
16 Heterocycle-fused indoles or indolines are core structures of various natural products, bioactive
17
18 agents and pharmaceuticals.^{1,2} Indoles fused with sp³-rich medium-sized rings are important
19
20 scaffolds that escape 'flatland' compound libraries for drug discovery.³ Propellane-type indolines
21
22 bearing a clear three-dimensional structure are also attractive because appropriate functional
23
24 groups can be introduced to the indoline template in the desired direction. In view of these features,
25
26 considerable efforts have been made to explore efficient strategies for the synthesis of those
27
28 structures.⁴⁻⁶
29
30

31
32 Gold-catalyzed cascade reactions are powerful synthetic methods for the construction of medium-
33
34 sized ring-fused indoles.⁵ In 2006, Echavarren et al. developed a facile annulation of eight-
35
36 membered ring-fused indoles by cyclization with alkyne in the presence of Au(III) species
37
38 (Scheme 1A).⁷ Our group has reported a direct and concise synthetic method for the generation of
39
40 2,3-fused indoles, using a gold-catalyzed cascade cyclization of diynes through an intramolecular
41
42 cascade 5-*endo-dig* hydroamination followed by a 6- or 7-*endo-dig* cycloisomerization (Scheme
43
44 1B).⁸ We also reported that gold-catalyzed cascade cyclization of 2-alkynyl-*N*-propargylanilines
45
46 provides propellane-type indolines via rearrangement of the propargyl group (Scheme 1C).⁹
47
48 Following these works, we have designed a direct synthetic method for the formation of eight-
49
50 membered ring-fused indoles, such as oxocine-fused indoles **2**, through an intramolecular cascade
51
52 5-*endo-dig* hydroamination followed by an 8-*endo-dig* cycloisomerization (Scheme 1D). During
53
54 the course of this study, we found that a propellane-type indoline **3** was obtained as a side product.
55
56
57
58
59
60

Echavarren and coworkers also observed related indoline formation in limited cases, depending on the substrate structure.^{7b} However, controllable formation of these two heterocycles from easily available diyne substrates based on reaction conditions has not been reported. Herein, we report ligand- and/or solvent-controlled divergent access to oxocine-fused indoles **2** and propellane-type indolines **3** via gold-catalyzed cascade cyclization (Scheme 1D).




Scheme 1. Related researches and this work.

RESULTS AND DISCUSSION

We initiated our study by optimizing the reaction conditions of the cascade cyclization of the *N*-methylaniline **1a** bearing two alkyne moieties (Table 1). The reaction of **1a** with 5 mol % PPh₃AuNTf₂ in *i*-PrOH at 80 °C yielded no observation of the desired oxocine-fused indole **2a**


(entry 1).¹⁰ Changing the catalyst to IPrAuNTf₂ gave the oxocine-fused indole **2a** in 65% yield along with, unexpectedly, a propellane-type indoline **3a** in 27% yield (entry 2). Use of IPrAuSbF₆·MeCN caused a decrease in the yield of **2a** (42%, entry 3). The reaction in MeOH and EtOH improved the yield of **2a** (74% and 82%, entries 4 and 5). Interestingly, when using 1,2-dichloroethane or toluene instead of *i*-PrOH as a solvent, the selectivity was switched, resulting in the favorable production of the propellane-type indoline **3a** (entries 6 and 7). Further investigation revealed that the reaction with Buchwald's type ligands such as JohnPhos or BrettPhos instead of IPr also gave indoline **3a** as the major form (entries 8–10). Taken together, choices of the catalysts and/or solvents were found to be crucial for controlling the formation of the two different products: the use of IPr ligands and alcoholic solvents provided the oxocine-fused indole **2a** predominantly, whereas the use of Buchwald's type ligands and/or non-polar solvents favored the formation of propellane-type indoline **3a**.

Table 1. Optimization of the reaction conditions.



Entry	Catalyst ^a	solvent	Temp (°C)	Yield (%) ^{b,c}	
				2a	3a
1	PPh ₃ AuNTf ₂	<i>i</i> -PrOH	80	0	0
2	IPrAuNTf ₂	<i>i</i> -PrOH	80	65	27
3	IPrAuSbF ₆ ·MeCN	<i>i</i> -PrOH	80	42	25
4	IPrAuNTf ₂	MeOH	60	74	9
5	IPrAuNTf ₂	EtOH	60	82 (85)	11 (7)
6	IPrAuNTf ₂	DCE	80	4	86
7	IPrAuNTf ₂	toluene	80	10	66
8	JohnPhosAuNTf ₂	<i>i</i> -PrOH	80	8 (8)	88 (81)

9	JohnPhosAuSbF ₆ ·MeCN	<i>i</i> -PrOH	80	6	86
10	BrettPhosAuNTf ₂	<i>i</i> -PrOH	80	8	80






^a The ligand structures are shown above. ^b Determined by ¹H NMR spectroscopy using 1,2,4,5-tetrachloro-3-nitrobenzene as an internal standard. ^c Yields in parentheses are the isolated yield on a 1.0 mmol scale.

With the two optimized reaction conditions for the formation of **2a** (Table 1, entry 5 as condition A) and **3a** (entry 8 as condition B) in hand, we proceeded to evaluate the substrate scope of the reaction (Table 2). The use of anilines with halogen (F, Cl, Br) groups at the *m*-position to the alkyne resulted in the formation of the desired products **2b** (68%), **2c** (64%) and **2d** (62%) under condition A, and **3b** (67%), **3c** (79%) and **3d** (82%) under condition B (entries 1–6). Anilines **1e** and **1f** bearing an electron-donating methyl or methoxy group also gave the desired fused-indoles **2e/f** and indolines **3e/f** (entries 7–10). Unfortunately, an electron-withdrawing cyano group-containing substrate **1g** gave much lower yields of **2g** (17% under condition A) and no propellane-type indoline products using both conditions (entries 11 and 12). The indole intermediate resulting from the first cyclization was observed. Thus, the poor yields of **2g** can be explained by the low nucleophilicity of the indole intermediate, assuming that a cyano group does not inhibit these reactions (*vide infra*, Table 3). The influence of the substituted position of the aniline substrates on the reaction course was evaluated using Br substituted derivatives. In the case of the aniline **1h** bearing a Br group at the *o*-position to the alkyne (entries 13 and 14), the reaction under condition A produced no oxocine-fused indole, whereas the reaction under condition B furnished propellane-type indoline **3h** in a moderate yield (44%). When using *m*- or *p*-brominated anilines **1i** and **1j**, respectively, the cascade reaction worked well to provide the corresponding oxocine-fused indoles

2i (64%) and **2j** (71%) under condition A, and propellane-type indolines **3i** (79%) and **3j** (80%) under condition B (entries 15–18). These results clearly demonstrated that steric repulsion between the *o*-Br group and phenyl group interferes with the formation of the oxocine of **2h**.

Table 2. Substrate scope (1).

Entry	Substrate	Condn.	Product (Isolated Yield)	
1		A	2b (68%)	3b (3%)
2	(R ¹ = F)	B	2b (22%)	3b (67%)
3	1c	A	2c (64%)	3c (trace)
4	(R ¹ = Cl)	B	2c (13%)	3c (79%)
5	1d	A	2d (62%)	3d (6%)
6	(R ¹ = Br)	B	2d (11%)	3d (82%)
7	1e	A	2e (77%)	3e (3%)
8	(R ¹ = Me)	B	2e (6%)	3e (77%)
9	1f	A	2f (75%)	3f (5%)
10	(R ¹ = OMe)	B	2f (16%)	3f (65%)
11	1g	A ^a	2g (17%)	3g (0%)
12	(R ¹ = CN)	B	2g (5%)	3g (0%)

13	1h	A	 2h (0%)	 3h (0%)
14		B	2h (0%)	3h (44%)
15	1i	A	 2i (64%)	3i (<19% ^b)
16		B	2i (6%)	3i (79%)
17	1j	A	 2j (71%)	3j (trace)
18		B	2j (9%)	3j (80%)







^a The second portion of IPrAuNTf₂ (5 mol %) was added after the reaction mixture was stirred for 6.5 h. ^b Containing small amounts of impurities.

Next, the substrate scope at the terminal phenyl ring was explored (Table 3). Electron-withdrawing halogen (Br, Cl) and cyano substituents at the *p*-position on the phenyl rings were tolerated by both conditions (**2k**: 73%, **2l**: 56% and **2m**: 73% under condition A, and **3k**: 77%, **3l**: 69% and **3m**: 74% under condition B). The reactions of **1n** or **1o** bearing an electron-donating groups (Me or MeO) at the *p*-position gave the corresponding fused indoles **2n** and **2o** in moderate or low yields using condition A (53% and 22%¹¹, respectively, entries 7 and 9).⁸ In contrast, the reaction of **1n** and **1o** under condition B gave the desired indolines **3n** and **3o**, respectively, in good yields (76% and 67%, entries 8 and 10). The evaluation of the substitution position on the phenyl ring was performed using Cl-substituted derivatives. The *m*-chloro derivative **1p** underwent the desired reaction to afford the corresponding **2p** and **3p** in good yields (entries 11 and 12). The

o-Cl derivative **1q** showed good reactivity to afford the fused indole **2q** in 70% yield, whereas condition B was less efficient, resulting in a lower yield of **2q** (27%) and selectivity (**2p**:**3p** = *ca.* 1:1; entry 14). The aniline **1r** bearing a naphth-2-yl group instead of a phenyl group provided the desired products **2r** and **3r** in 63% and 52% yields, respectively (entries 15 and 16). In contrast, the aniline **1s** bearing a methyl group at the alkyne terminus displayed low reactivity in the formation of **2s** and **3s** (entries 17 and 18). In this case, using DCE as the solvent, afforded the propellane-type indoline **3s** in good yield (82%, entry 19).

Table 3. Substrate scope (2).

Entry	Substrate (R ²)	Condn.	Product (Isolated Yield)	
1		A	2k (73%)	3k (<10% ^a)
2	1k (R ² = Cl)	B	2k (8%)	3k (77%)
3		A	2l (56%)	3l (<15% ^a)
4	1l (R ² = Br)	B	2l (4%)	3l (69%)
5		A	2m (73%)	3m (<11% ^a)
6	1m (R ² = CN)	B	2m (6%)	3m (74%)
7		A ^b	2n (53%)	3n (12%)
8	1n (R ² = Me)	B	2n (10%)	3n (76%)
9	1o	A ^b	2o (22%)	3o (<14% ^a)

10	(R ² = OMe)	B	2o (0%)	3o (67%)
				
11	1p	A	2p (71%)	3p (<7% ^a)
12		B	2p (8%)	3p (74%)
				
13	1q	A	2q (70%)	3q (<12% ^a)
14		B	2q (27%)	3q (26%)
				
15	1r	A	2r (63%)	3r (<9% ^a)
16		B	2r (0%)	3r (52%)
				
17	1s	A ^c	2s (16%)	3s (8%)
18		B	2s (5%)	3s (34%)
19		C ^d	2s (trace)	3s (82%)





^aContaining small amounts of impurities. ^bThe second portion of IPrAuNTf₂ (5 mol %) was added after the reaction mixture was stirred for 1 h. ^cThe reaction was carried out in *i*-PrOH using IPrAuNTf₂ (5 mol %) and MS3Å at 80 °C. ^dThe reaction was carried out under entry 6 of Table 1.

We next examined the reaction of substrates bearing a variety of functional groups on anilines and linker moieties (Table 4). The use of unprotected aniline derivative **1t** provided the desired


products **2t** and **3t** in low yields under respective conditions (entries 1 and 2). Changing the methyl group to a benzyl group did not affect the cascade reaction (entries 3 and 4). When using **1v** bearing a shorter carbon tether ($n = 0$), the seven-membered ring-fused indole **2v** was obtained in 63% yield (condition A) and 44% yield (condition B). However, no propellane-type indoline **3v** was observed under both conditions (entries 5 and 6), presumably because of the ring strain in **3v**. The use of **1w** bearing a longer carbon tether ($n = 2$) did not afford the nine-membered ring-fused indoles **2w**; however, the propellane-type indoline **3w** was produced under condition B but in low yield (28%, entry 8). In sharp contrast, treatment of sulfonamide **1x** under conditions A and B produced only the ring-fused indole **2x** (67% and 63%, respectively) without producing the propellane-type indoline **3x** (entries 9 and 10).

Table 4. Substrate scope (3).

Entry	Substrate (R^3 , n , Z)	Condn.	Product (Isolated Yield)	
1	1t	A	2t (32%)	3t (7%)
2	(H, 1, O)	B	2t (0%)	3t (18%)
3	1u	A	2u (56%)	3u (trace)
4	(Bn, 1, O)	B	2u (8%)	3u (77%)
5	1v	A	2v (63%)	3v (0%)


6	(Me, 0, O)	B	2v (44%)	3v (0%)
				
7	1w	A	2w (0%)	3w (0%)
8	(Me, 2, O)	B	2w (0%)	3w (28%)
				
9	1x	A	2x (63%)	3x (0%)
10	(Me, 1, NTs)	B	2x (67%)	3x (0%)

We conducted several experiments to gain insight into the mechanism of the cascade reaction (Scheme 2). Initially, the cascade reaction was performed at lower temperature (40 °C), which resulted in the production of an allene **4a** as a plausible intermediate, along with the fused indole **2a** and indoline **3a**. Interestingly, allene **4a** subjected to condition A (favoring the formation of the oxocine-fused indoles **2**) afforded **2a** (4%) and **3a** (91%).⁹ These results strongly indicated that the allene **4a** is the intermediate of the propellane-type indoline **3a** and not the oxocine-fused indole **2a**.



Scheme 2. Gold-catalyzed cyclization of **1a**.


Next, an optically active **1y** with a methyl group at the propargylic position was prepared. We first expected that the cascade reaction of **1y** would give the corresponding optically active oxocine-fused indole **2y** as a single enantiomer, via *5-endo-dig* hydroamination and *8-endo-dig* cycloisomerization followed by protodeauration of **1yC** (Scheme 3). Quite surprisingly, the reaction of (*S*)-**1y** under condition A provided the fused indole **2y** (35% yield) and the indoline **3y** (35% yield) with complete loss of optical activity [The reaction of (*S*)-**1y** under condition B gave the oxocine-fused indole **2y** (<31 %, 0 % ee) without providing propellane-type indoline **3y**]¹². Additionally, the reaction of **1y** was conducted with the shorter reaction time or the lower reaction temperature to give the corresponding allene intermediates **4y**, whose optical activities were also lost completely.¹³ These results suggested that the catalytic cycle involves the formation of an achiral cationic intermediate such as **1yD**, resulting from the ring-opening reaction of vinyl-gold intermediate **1yC**.^{7b} Formation of racemic **2y** and **3y** is rationalized by gold-catalyzed cyclization of the vinyl-gold derivative **1yD**. However, racemization of the optically active allene **4y** by the action of the gold catalyst cannot be ruled out.¹⁴



Scheme 3. Gold-catalyzed cyclization of **1y**.

1
2
3
4
5
6
7
8 On the basis of these experiments, a proposed reaction mechanism is shown in Scheme 4. As
9 reported in our previous work,⁸ activation of the alkyne by cationic gold, as depicted in **A**,
10 promotes *5-endo-dig* cyclization followed by protodeauration to give the indole **5**. Subsequently,
11 the activation of the second alkyne leads to the *8-endo-dig* hydroarylation of **5** to form a vinyl-
12 gold intermediate **C**. The eight-membered ring of intermediate **C** is easily opened to generate a
13 cationic intermediate **D**, which could return to **C** by nucleophilic attack of the hydroxy group to
14 the highly reactive conjugated diene. Intermediate **C** undergoes protodeauration to generate the
15 oxocine-fused indole **2**. Alternatively, elimination of gold from intermediate **D** may occur to
16 provide allene **4**,¹⁵ which is converted to the propellane-type indoline **3**, as we reported previously.⁹
17 The reverse reaction of allene **4** to vinyl-gold **C** should be much slower than formation of **G**
18 because the reaction of **4a** produced only a small amount of **2a** under condition A (4%, Scheme
19 2). Noteworthy, Bi et al. have computationally demonstrated that direct formation of the cationic
20 intermediate **G** from **E** by reaction at the indole 2 position is favored over the ring expansion
21 pathway through the four-membered ring **F**.¹⁶
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The significant effects of the reaction solvent and ligand can be partly rationalized as follows:
40 protic solvents such as alcohol promote protodeauration of vinyl-gold intermediate **C**, thus
41 contributing to the formation of oxocine-fused indoles (Table 1, entries 2–5). Electron-donating
42 ligands such as IPr ligands are also known to accelerate protodeauration,¹⁷ resulting in the
43 predominant formation of the fused indoles. However, further investigation is necessary to
44 elucidate the effects of the ligand.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 4. Proposed reaction mechanism.

CONCLUSION

In conclusion, we have developed controllable formation of eight-membered ring-fused indoles and propellane-type indolines via gold-catalyzed cascade cyclization. This reaction gives quick access to various ring-fused indoles and indolines from simple aniline derivatives, depending on the ligands or solvents employed. Examination with an aniline derivative bearing a chiral center demonstrated that these types of cascade cyclization reactions proceed via the ring-opened intermediate **D**. Further studies including an investigation of the exact reaction mechanism and application to the synthesis of biologically-active compounds are now in progress.

EXPERIMENTAL SECTION

General Methods. ¹H NMR spectra were recorded using a JEOL ECA-500 spectrometer at 500 MHz frequency. Chemical shifts are reported in δ (ppm) relative to Me₄Si [in CDCl₃ or DMSO]

1
2
3
4
5
6 as internal standard. ^{13}C NMR spectra were recorded using a JEOL ECA-500 and a JNM ECZ600R,
7
8 and referenced to the residual solvent signal. IR spectra were obtained on a JASCO FT/IR-4100
9
10 spectrometer. Exact mass (HRMS) spectra were recorded on a Shimadzu LC-ESI-IT-TOF-MS
11
12 equipment (ESI). Column chromatography was performed using a forced flow (flash
13
14 chromatography) of the indicated solvent system on Wakogel C-300E (Wako), Chromatorex NH-
15
16 DM1020 (Fuji Silysia) or Biotage Isolera flash purification system on Presep[®] Silica Gel Type M
17
18 (Wako), Presep[®] Silica Gel Type L (Wako) or Biotage ZIP[®] ISOLUTE NH (Biotage). All the
19
20 heating experiments were performed in an oil bath. The Compounds **S1b**, **S1c**, **S1g**, **S1i**, **S1j**, **S3a**,
21
22 **S3b**, **S3c** are commercially available. The known Compounds **S1h**¹⁸, **S1j**¹⁹, **S2a**²⁰, **S2d**⁹, **S2e**⁹, **S2f**⁹,
23
24 **S2k**⁹, **S3d**²¹, **S4**²², **S5f**²³, **S5g**²⁴, **S6**²⁵ were synthesized according to the literatures. The ^1H NMR
25
26 spectra of **S2c**²⁶, **S2g**²⁷ and **S5b**²⁸ were in good accordance with those reported in literature.
27
28 Structures of **S1a**, **S1b**, **S1c**, **S1g**, **S1h**, **S1i**, **S1j**, **S2a-S2j**, **S3a-S3d**, **S4**, **S5a-S5e**, **S6**, **S7**, **S8** are
29
30 shown in Schemes S1-S5.
31
32
33
34
35

36 **Preparation of the Cyclization Precursor.**

37
38
39
40 **4-Fluoro-2-iodo-N-methylaniline (S2b).** To a stirred solution of 4-fluoro-2-iodoaniline (**S1b**)
41
42 (1.16 g, 4.90 mmol) in THF (16 mL) was added MeLi (1.16 M in Et₂O; 4.65 mL, 5.39 mmol) at –
43
44 78 °C under argon. After the mixture was stirred for 1 h at this temperature, MeI (0.366 mL, 5.89
45
46 mmol) was added to the mixture. The mixture was gradually warmed to room temperature and
47
48 stirred for 12 h at this temperature. The reaction was quenched with saturated aqueous NH₄Cl. The
49
50 resulting mixture was extracted with EtOAc twice. The combined organic layer was washed with
51
52 brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column
53
54 chromatography on silica gel (hexane/EtOAc = 40/1) to give **S2b** (630 mg, 51%) as a red oil; IR
55
56
57
58
59
60

(neat cm^{-1}): 3408 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.83 (s, 3H), 3.95-4.04 (br m, 1H), 6.45 (dd, $J = 8.9, 4.9$ Hz, 1H), 6.98 (ddd, $J = 8.9, 8.9, 2.9$ Hz, 1H), 7.40 (dd, $J = 8.0, 2.9$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 31.5, 83.4 (d, $J_{\text{C-F}} = 8.4$ Hz), 109.5 (d, $J_{\text{C-F}} = 7.2$ Hz), 115.8 (d, $J_{\text{C-F}} = 21.6$ Hz), 125.3 (d, $J_{\text{C-F}} = 25.2$ Hz), 145.1 (d, $J_{\text{C-F}} = 2.4$ Hz), 154.5 (d, $J_{\text{C-F}} = 238.7$ Hz); HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_7\text{H}_7\text{FIN}$ 251.9680; found 251.9679.

4-Chloro-2-iodo-*N*-methylaniline (S2c). According to the procedure described for the preparation of **S2b**, 4-chloro-2-iodoaniline (**S1c**) (991 mg, 3.91 mmol) was converted into **S2c** (271 mg, 26%) by the reaction with MeLi (1.16 M in Et_2O ; 4.05 mL, 4.69 mmol) and MeI (292 μL , 4.69 mmol) in THF (6.5 mL) at -78 $^\circ\text{C}$ to room temperature for 5 h. Column chromatography: silica gel (gradient 1% to 5% EtOAc in hexane); ^1H NMR (500 MHz, CDCl_3) δ : 2.87 (d, $J = 5.2$ Hz, 3H), 4.15-4.24 (br m, 1H), 6.45 (d, $J = 8.6$ Hz, 1H), 7.20 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.62 (d, $J = 2.3$ Hz, 1H). The ^1H NMR spectra was in good agreement with that reported.²⁶

3-Iodo-4-(methylamino)benzotrile (S2g). According to the procedure described for the preparation of **S2b**, 4-amino-3-iodobenzotrile (**S1g**) (452 mg, 1.85 mmol) was converted into **S2g** (210 mg, 44%) by the reaction with MeLi (1.16 M in Et_2O ; 1.91 mL, 2.22 mmol) and MeI (150 μL , 2.41 mmol) in THF (6.2 mL) at -78 $^\circ\text{C}$ to room temperature for 1 h. Column chromatography: silica gel (hexane/EtOAc = 10/1); ^1H NMR (400 MHz, CDCl_3) δ : 2.94 (d, $J = 5.2$ Hz, 3H), 4.76-4.85 (br m, 1H), 6.49 (d, $J = 8.6$ Hz, 1H), 7.48 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.88 (d, $J = 1.7$ Hz, 1H). The ^1H NMR spectra was in good agreement with that reported.²⁷

3-Bromo-2-iodo-*N*-methylaniline (S2h). According to the procedure described for the preparation of **S2b**, 3-bromo-2-iodoaniline (**S1h**) (244 mg, 0.818 mmol) was converted into **S2h** (78.9 mg, 31%) by the reaction with MeLi (1.16 M in Et_2O ; 0.847 mL, 0.982 mmol) and MeI (65.9

1
2
3
4
5
6 μL , 1.06 mmol) in THF (2.7 mL) at $-78\text{ }^\circ\text{C}$ to room temperature for 10 h. Column chromatography:
7
8 (gradient 1% to 5% EtOAc in hexane) and amine silica gel (hexane only); colorless oil; IR (neat
9
10 cm^{-1}): 3401 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.88 (d, $J = 5.2$ Hz, 3H), 4.47-4.58 (br m, 1H),
11
12 6.43 (d, $J = 8.0$ Hz, 1H), 7.00 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.10 (dd, $J = 8.0, 8.0$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$
13
14 NMR (125 MHz, CDCl_3) δ : 31.4, 92.0, 107.7, 120.8, 130.1, 130.5, 150.6; HRMS (ESI-TOF) m/z :
15
16 $[\text{M} + \text{H}]^+$ calcd for $\text{C}_7\text{H}_8\text{BrIN}$ 311.8879; found 311.8874.
17
18
19

20
21 **5-Bromo-2-iodo-*N*-methylaniline (S2i)**. According to the procedure described for the
22
23 preparation of **S2b**, 5-bromo-2-iodoaniline (**S1i**) (473 mg, 1.59 mmol) was converted into **S2i** (335
24
25 mg, 68%) by the reaction with MeLi (1.16 M in Et_2O ; 1.64 mL, 1.91 mmol) and MeI (129 μL ,
26
27 2.06 mmol) in THF (5.3 mL) at $-78\text{ }^\circ\text{C}$ to room temperature for 10 h. Column chromatography:
28
29 (gradient 1% to 5% EtOAc in hexane); yellow solid; mp $78\text{-}80\text{ }^\circ\text{C}$; IR (neat cm^{-1}): 3401 (NH); ^1H
30
31 NMR (500 MHz, CDCl_3) δ : 2.87 (d, $J = 5.2$ Hz, 3H), 4.23-4.29 (br m, 1H), 6.57 (dd, $J = 8.6, 2.3$
32
33 Hz, 1H), 6.64 (d, $J = 2.3$ Hz, 1H), 7.46 (d, $J = 8.6$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ :
34
35 30.8, 82.7, 112.7, 121.1, 123.7, 139.6, 149.2; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_7\text{H}_8\text{BrIN}$
36
37 311.8879; found 311.8880.
38
39
40

41
42 **[3-(But-3-yn-1-yloxy)prop-1-yn-1-yl]benzene (S5a)**. To a suspension of NaH (532 mg, 13.3
43
44 mmol) in anhydrous THF (15 mL) at $0\text{ }^\circ\text{C}$ was added dropwise 3-butyn-1-ol (**S3a**) (777 mg, 11.1
45
46 mmol). After the mixture was stirred for 30 min, a solution of (3-bromoprop-1-yn-1-yl)benzene
47
48 (**S4**) (2.38 g, 12.2 mmol) in THF (3.5 mL) was added to the reaction mixture at $0\text{ }^\circ\text{C}$. The mixture
49
50 was stirred at room temperature for additional 7.5 h, and then diluted with water. The resulting
51
52 mixture was extracted with EtOAc twice. The combined organic layer was washed with brine,
53
54 dried over Na_2SO_4 , filtered, and concentrated in vacuo. The residue was purified by column
55
56
57
58
59
60

1
2
3
4
5
6 chromatography on silica gel (gradient 1% to 5% EtOAc in hexane) to give **S5a** (1.46 g, 73%) as
7
8 a yellow oil; IR (neat cm^{-1}): 2235 ($\text{C}\equiv\text{C}$); ^1H NMR (500 MHz, CDCl_3) δ : 2.02 (t, $J = 2.9$ Hz, 1H),
9
10 2.54 (td, $J = 6.9, 2.9$ Hz, 2H), 3.73 (t, $J = 6.9$ Hz, 2H), 4.43 (s, 2H), 7.28-7.34 (m, 3H), 7.43-7.47
11
12 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 19.7, 58.9, 67.9, 69.4, 81.0, 84.7, 86.4, 122.5, 128.3
13
14 (2C), 128.5, 131.7 (2C); HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{13}\text{H}_{12}\text{NaO}$ 207.0780; found
15
16 207.0779.
17
18
19

20
21 **[3-(Prop-2-yn-1-yloxy)prop-1-yn-1-yl]benzene (S5b)**. According to the procedure described
22
23 for the preparation of **S5a**, pent-4-yn-1-ol (**S3b**) (0.135 mL, 2.29 mmol) was converted into **S5b**
24
25 (155 mg, 40%) by the reaction with **S4** (491 mg, 2.52 mmol) in THF (1.3 mL), NaH (82.3 mg,
26
27 3.43 mmol) in THF (2.5 mL) at room temperature for 5 h. Column chromatography: silica gel
28
29 (gradient 1% to 3% EtOAc in hexane); ^1H NMR (500 MHz, CDCl_3) δ : 2.48 (t, $J = 2.4$ Hz, 1H),
30
31 4.33 (d, $J = 2.4$ Hz, 2H), 4.50 (s, 2H), 7.30-7.50 (m, 5H). The ^1H NMR spectra was in good
32
33 agreement with that reported.²⁸
34
35
36

37
38 **[3-(Hex-5-yn-1-yloxy)prop-1-yn-1-yl]benzene (S5c)**. According to the procedure described for
39
40 the preparation of **S5a**, pent-4-yn-1-ol (**S3c**) (0.221 mL, 2.38 mmol) was converted into **S5c** (382
41
42 mg, 81%) by the reaction with **S4** (464 mg, 2.38 mmol) in THF (1.0 mL), NaH (105 mg, 2.62
43
44 mmol) in THF (2.0 mL) at room temperature for 6.5 h. Column chromatography: silica gel
45
46 (gradient 1% to 5% EtOAc in hexane); yellow oil; IR (neat cm^{-1}): 2335 ($\text{C}\equiv\text{C}$); ^1H NMR (500
47
48 MHz, CDCl_3) δ : 1.85 (tt, $J = 6.3, 6.3$ Hz, 2H), 1.95 (t, $J = 2.6$ Hz, 1H), 2.33 (td, $J = 6.3, 2.6$ Hz,
49
50 2H), 3.69 (t, $J = 6.3$ Hz, 2H), 4.37 (s, 2H), 7.28-7.33 (m, 3H), 7.42-7.47 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR
51
52 (125 MHz, CDCl_3) δ : 15.2, 28.5, 58.9, 68.4, 68.5, 83.8, 85.2, 86.1, 122.6, 128.2 (2C), 128.4, 131.7
53
54 (2C); HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{15}\text{O}$ 199.1117; found 199.1118.
55
56
57
58
59
60

1
2
3
4
5
6 ***N*-(But-3-yn-1-yl)-4-methyl-*N*-(3-phenylprop-2-yn-1-yl)benzenesulfonamide (S5d).** A
7
8 mixture of *N*-(but-3-yn-1-yl)-4-methylbenzenesulfonamide (**S3d**) (185 mg, 0.829 mmol) and
9
10 K₂CO₃ (229 mg, 1.66 mmol) in dry MeCN (6.0 mL) was added **S4** (178 mg, 0.911 mmol) in dry
11
12 MeCN (2.3 mL) at room temperature. The mixture was stirred under reflux for 2 h, and then diluted
13
14 with water. The resulting mixture was extracted with EtOAc twice. The combined organic layer
15
16 was washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was
17
18 purified by column chromatography on silica gel (gradient 6% to 19% EtOAc in hexane) to give
19
20 **S5d** (261 mg, 93%) as a white solid; mp 84-85 °C; IR (neat cm⁻¹): 2253 (C≡C), 1160 (S=O), 1348
21
22 (S=O); ¹H NMR (500 MHz, CDCl₃) δ: 2.03 (t, *J* = 2.6 Hz, 1H), 2.34 (s, 3H), 2.57 (td, *J* = 7.4, 2.6
23
24 Hz, 2H), 3.44 (t, *J* = 7.4 Hz, 2H), 4.42 (s, 2H), 7.09 (d, *J* = 8.6 Hz, 2H), 7.22-7.30 (m, 5H), 7.78
25
26 (d, *J* = 8.6 Hz, 2H); ¹³C {¹H} NMR (125 MHz, CDCl₃) δ: 19.0, 21.4, 38.1, 45.5, 70.3, 80.8, 81.7,
27
28 85.6, 121.9, 127.6 (2C), 128.1 (2C), 128.5, 129.5 (2C), 131.4 (2C), 135.7, 143.6; HRMS (ESI-
29
30 TOF) *m/z*: [M + H]⁺ calcd for C₂₀H₁₉NO₂S 338.1209; found 338.1205.
31
32
33
34
35

36 **(*S*)-[3-(But-3-yn-1-yloxy)but-1-yn-1-yl]benzene (S5e).** To a suspension of NaH (651 mg, 16.3
37
38 mmol) in anhydrous THF (16 mL) at 0 °C was added dropwise a solution of (*S*)-4-phenylbut-3-
39
40 yn-2-ol (**S6**) (1.83 g, 12.5 mmol) in THF (4.9 mL). After the mixture was stirred for 30 min, 3-
41
42 bromopropan-1-ol (2.09 g, 15.0 mmol) was added to the reaction mixture at 0 °C. The mixture was
43
44 stirred at room temperature for additional 7 h, and then diluted with water. The resulting mixture
45
46 was extracted with EtOAc twice. The combined organic layer was washed with brine, dried over
47
48 Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography
49
50 on silica gel (gradient 5% to 30% EtOAc in hexane) to give **S7** (1.14 g, <45%), including
51
52 inseparable impurities, as a yellow oil. To a solution of **S7** (1.14 g, *ca.* 7.80 mmol) including
53
54 impurities in CH₂Cl₂ (7.8 mL) were added TEMPO (122 mg, 0.78 mmol) and DAIB (2.77 g, 8.59
55
56
57
58
59
60

mmol) at room temperature. After being stirred for 2 h, the mixture was washed with a saturated aqueous solution of Na₂S₂O₃ and extracted with CH₂Cl₂ twice. The combined organic extracts were washed with aqueous NaHCO₃ and brine, dried over Na₂SO₄, filtered, and concentrated in vacuo to give crude **S8** as a red oil. To a solution of crude **S8** in MeOH (9.8 mL) were added Bestmann Reagent (1.65 g, 8.59 mmol) and K₂CO₃ (1.29 g, 9.37 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 2 h. The reaction was quenched with saturated aqueous NH₄Cl. The resulting mixture was extracted with EtOAc twice. The combined organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (gradient 2% to 5% EtOAc in hexane) to give **S5e** (352 mg, 23%, 2 steps) as a colorless oil; $[\alpha]_D^{25} -150.0$ (*c* 1.24, CHCl₃); IR (neat cm⁻¹): 2249 (C≡C); ¹H NMR (500 MHz, CDCl₃) δ: 1.52 (d, *J* = 6.7 Hz, 3H), 2.00 (t, *J* = 2.7 Hz, 1H), 2.52 (ddd, *J* = 7.0, 7.0, 2.7 Hz, 2H), 3.60 (dt, *J* = 12.6, 7.0 Hz, 1H), 3.90 (dt, *J* = 12.6, 7.0 Hz, 1H), 4.43 (q, *J* = 6.7 Hz, 1H), 7.27-7.32 (m, 3H), 7.41-7.46 (m, 2H); ¹³C {¹H} NMR (125 MHz, CDCl₃) δ: 19.8, 22.0, 65.8, 66.6, 69.3, 81.1, 85.0, 88.7, 122.5, 128.2 (2C), 128.3, 131.6 (2C); HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₄H₁₅O 199.1117; found 199.1123.

***N*-Methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1a).** A mixture of 2-iodo-*N*-methylaniline (**S2a**) (1.43 g, 6.1 mmol), **S5a** (1.24 g, 6.7 mmol), PdCl₂(PPh₃)₂ (216 mg, 0.3 mmol), CuI (58.0 mg, 0.3 mmol), and Et₃N (2.7 mL, 18 mmol) in DMF (20 mL) was stirred at room temperature under Ar for 11 h. The mixture was diluted with saturated aqueous NH₄Cl. The resulting mixture was extracted with EtOAc twice. The combined organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (hexane/acetone = 20/1) to give **1a** (1.03 g, 58%) as a purple oil; IR (neat cm⁻¹): 3297 (NH); ¹H NMR (500 MHz, CDCl₃) δ: 2.82 (t, *J* = 6.9 Hz, 2H), 2.87 (d, *J* = 5.2

1
2
3
4
5
6 Hz, 3H), 3.82 (t, $J = 6.9$ Hz, 2H), 4.46 (s, 2H), 4.69-4.74 (br m, 1H), 6.55 (d, $J = 8.0$ Hz, 1H), 6.59
7
8 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.18 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.24 (d, $J = 8.0$ Hz, 1H), 7.28-7.34 (m,
9
10 3H), 7.43-7.47 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.0, 30.2, 58.9, 68.3, 78.4, 84.9,
11
12 86.4, 92.2, 107.7, 108.7, 115.9, 122.5, 128.3 (2C), 128.5, 129.4, 131.7 (3C), 150.0; HRMS (ESI-
13
14 TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{NO}$ 290.1539; found 290.1540.

15
16
17
18 **4-Fluoro-*N*-methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1b).**

19
20 According to the procedure described for the preparation of **1a**, 4-fluoro-2-iodo-*N*-methylaniline
21
22 (**S2b**) (293 mg, 1.17 mmol) was converted into **1b** (247 mg, 69%) by the reaction with **S5a** (236
23
24 mg, 1.28 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (40.9 mg, 0.0583 mmol), CuI (11.1 mg, 0.0583 mmol) and Et_3N
25
26 (0.51 mL) in DMF (3.9 mL) at room temperature for 6 h. Column chromatography: silica gel
27
28 (hexane/acetone = 20/1) : yellow oil; IR (neat cm^{-1}): 3422 (NH); ^1H NMR (500 MHz, CDCl_3) δ :
29
30 2.82 (t, $J = 6.9$ Hz, 2H), 2.85 (d, $J = 5.2$ Hz, 3H), 3.82 (t, $J = 6.9$ Hz, 2H), 4.46 (s, 2H), 4.52-4.59
31
32 (br m, 1H), 6.45 (dd, $J = 8.9, 4.9$ Hz, 1H), 6.91 (ddd, $J = 8.9, 8.9, 2.9$ Hz, 1H), 6.97 (dd, $J = 8.9,$
33
34 2.9 Hz, 1H), 7.28-7.35 (m, 3H), 7.43-7.47 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 20.9,
35
36 30.7, 59.0, 68.1, 77.5, 84.7, 86.5, 93.2, 108.2 (d, $J_{\text{C-F}} = 9.6$ Hz), 109.3 (d, $J_{\text{C-F}} = 8.4$ Hz), 116.1 (d,
37
38 $J_{\text{C-F}} = 22.8$ Hz), 117.9 (d, $J_{\text{C-F}} = 22.8$ Hz), 122.4, 128.3 (2C), 128.5, 131.7 (2C), 146.8, 154.2 (d,
39
40 $J_{\text{C-F}} = 233.9$ Hz); HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{FNO}$ 308.1445; found
41
42 308.1450.

43
44
45
46
47
48 **4-Chloro-*N*-methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1c).**

49
50 According to the procedure described for the preparation of **1a**, 4-chloro-2-iodo-*N*-methylaniline
51
52 (**S2c**) (259 mg, 0.966 mmol) was converted into **1c** (218 mg, 41%) by the reaction with **S5a** (192
53
54 mg, 1.06 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (33.9 mg, 0.0483 mmol), CuI (9.20 mg, 0.0483 mmol) and Et_3N
55
56 (0.42 mL) in DMF (3.2 mL) at room temperature for 5 h. Column chromatography: silica gel
57
58
59
60

(hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}): 3410 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.81 (t, $J = 6.9$ Hz, 2H), 2.84 (d, $J = 5.2$ Hz, 3H), 3.81 (t, $J = 6.9$ Hz, 2H), 4.46 (s, 2H), 4.69-4.74 (br m, 1H), 6.45 (d, $J = 8.6$ Hz, 1H), 7.12 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.20 (d, $J = 2.3$ Hz, 1H), 7.28-7.34 (m, 3H), 7.43-7.46 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.0, 30.3, 59.0, 68.1, 77.3, 84.7, 86.5, 93.4, 109.0, 109.7, 120.2, 122.4, 128.3 (2C), 128.5, 129.2, 131.0, 131.7 (2C), 148.6; HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{18}\text{ClNNaO}$ 346.0969; found 346.0966.

4-Bromo-*N*-methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1d).

According to the procedure described for the preparation of **1a**, 4-bromo-2-iodo-*N*-methylaniline (**S2d**) (195 mg, 0.624 mmol) was converted into **1d** (159 mg, 69%) by the reaction with **S5a** (127 mg, 0.687 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (21.9 mg, 0.0312 mmol), CuI (5.94 mg, 0.0312 mmol) and Et_3N (0.27 mL) in DMF (2.1 mL) at room temperature for 7 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}): 3414 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.81 (t, $J = 6.6$ Hz, 2H), 2.84 (d, $J = 5.2$ Hz, 3H), 3.81 (t, $J = 6.6$ Hz, 2H), 4.46 (s, 2H), 4.70-4.76 (br m, 1H), 6.41 (d, $J = 8.6$ Hz, 1H), 7.23-7.26 (m, 1H), 7.28-7.35 (m, 4H), 7.43-7.46 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.0, 30.2, 59.0, 68.1, 77.2, 84.7, 86.5, 93.6, 106.9, 109.5, 110.2, 122.4, 128.3 (2C), 128.5, 131.7 (2C), 132.1, 133.8, 149.0; HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{18}\text{BrNNaO}$ 390.0464; found 390.0461.

***N*,4-Dimethyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1e).** According to the procedure described for the preparation of **1a**, 2-iodo-*N*,4-dimethylaniline (**S2e**) (260 mg, 1.05 mmol) was converted into **1e** (185 mg, 58%) by the reaction with **S5a** (213 mg, 1.16 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (37.0 mg, 0.0527 mmol), CuI (10.0 mg, 0.0527 mmol) and Et_3N (0.46 mL) in DMF (3.5 mL) at room temperature for 9 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}): 3407 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.19 (s, 3H), 2.81 (t, $J = 6.9$

1
2
3
4
5
6 Hz, 2H), 2.85 (d, $J = 4.0$ Hz, 3H), 3.82 (t, $J = 6.9$ Hz, 2H), 4.46 (s, 2H), 4.51-4.56 (br m, 1H), 6.48
7
8 (d, $J = 8.0$ Hz, 1H), 7.00 (d, $J = 8.0$ Hz, 1H), 7.08 (s, 1H), 7.28-7.35 (m, 3H), 7.44-7.47 (m, 2H);
9
10 $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 20.1, 21.0, 30.5, 59.0, 68.3, 78.5, 84.8, 86.4, 91.8, 107.6,
11
12 108.9, 122.5, 125.0, 128.2 (2C), 128.5, 130.0, 131.7 (2C), 132.1, 147.9; HRMS (ESI-TOF) m/z :
13
14 $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}$ 304.1696; found 304.1694.
15
16
17

18 **4-Methoxy-*N*-methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1f).**

19
20 According to the procedure described for the preparation of **1a**, 2-bromo-4-methoxy-*N*-
21
22 methylaniline (**S2f**) (365 mg, 1.69 mmol) was converted into **1f** (92.1 mg, 17%) by the reaction
23
24 with **S5a** (335 mg, 1.86 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (59.2 mg, 0.0843 mmol), CuI (16.1 mg, 0.0843
25
26 mmol) and Et_3N (0.74 mL) in DMF (5.6 mL) at 80 °C for 5 h. Column chromatography: silica gel
27
28 (hexane/acetone = 20/1 and gradient 2% to 15% EtOAc in hexane): blue oil; IR (neat cm^{-1}): 3407
29
30 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.82 (t, $J = 6.6$ Hz, 2H), 2.84 (s, 3H), 3.72 (s, 3H), 3.82 (t,
31
32 $J = 6.6$ Hz, 2H), 4.37-4.40 (br m, 1H), 4.46 (s, 2H), 6.51 (d, $J = 8.6$ Hz, 1H), 6.82 (dd, $J = 8.6, 2.9$
33
34 Hz, 1H), 6.86 (d, $J = 2.9$ Hz, 1H), 7.28-7.34 (m, 3H), 7.43-7.47 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz,
35
36 CDCl_3) δ : 21.0, 31.0, 55.9, 59.0, 68.2, 78.3, 84.8, 86.4, 92.3, 108.3, 110.1, 116.3, 116.8, 122.5,
37
38 128.3 (2C), 128.5, 131.8 (2C), 145.0, 150.6; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_2$
39
40 320.1645; found 320.1641.
41
42
43
44
45

46 **4-(Methylamino)-3-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}benzotrile (1g).**

47
48 According to the procedure described for the preparation of **1a**, 3-iodo-4-
49
50 (methylamino)benzotrile (**S2g**) (195 mg, 0.757 mmol) was converted into **1g** (199 mg, 84%) by
51
52 the reaction with **S5a** (153 mg, 0.833 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (26.6 mg, 0.0379 mmol), CuI (7.21
53
54 mg, 0.0379 mmol) and Et_3N (0.33 mL) in DMF (2.5 mL) at room temperature for 8 h. Column
55
56 chromatography: silica gel (hexane/acetone = 20/1 and gradient 1% to 25% EtOAc in hexane):
57
58
59
60

orange oil; IR (neat cm^{-1}): 3410 (NH), 2217 ($\text{C}\equiv\text{N}$); ^1H NMR (500 MHz, CDCl_3) δ : 2.81 (t, $J = 6.3$ Hz, 2H), 2.90 (d, $J = 5.2$ Hz, 3H), 3.82 (t, $J = 6.3$ Hz, 2H), 4.46 (s, 2H), 5.34-5.39 (br m, 1H), 6.50 (d, $J = 8.6$ Hz, 1H), 7.28-7.34 (m, 3H), 7.41 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.42-7.45 (m, 2H), 7.47 (d, $J = 1.7$ Hz, 1H); ^{13}C $\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 20.9, 29.8, 59.0, 67.9, 76.3, 84.6, 86.6, 94.4, 97.6, 108.2, 108.3, 120.0, 122.3, 128.3 (2C), 128.6, 131.7 (2C), 133.4, 135.2, 152.5; HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{NaO}$ 337.1311; found 337.1304.

3-Bromo-*N*-methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1h).

According to the procedure described for the preparation of **1a**, **S2h** (163 mg, 0.524 mmol) was converted into **1h** (37.3 mg, 19%) by the reaction with **S5a** (106 mg, 0.576 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (18.4 mg, 0.0262 mmol), CuI (4.99 mg, 0.0262 mmol) and Et_3N (0.23 mL) in DMF (1.7 mL) at room temperature for 11 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}): 3413 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.84-2.90 (m, 5H), 3.85 (t, $J = 6.6$ Hz, 2H), 4.48 (s, 2H), 4.94-5.00 (br m, 1H), 6.46 (d, $J = 8.3$ Hz, 1H), 6.84 (d, $J = 8.3$ Hz, 1H), 7.00 (dd, $J = 8.3, 8.3$ Hz, 1H), 7.28-7.35 (m, 3H), 7.42-7.47 (m, 2H); ^{13}C $\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.2, 30.3, 59.0, 68.1, 77.5, 84.7, 86.5, 97.0, 107.1, 109.5, 119.4, 122.4, 125.2, 128.3 (2C), 128.5, 129.7, 131.7 (2C), 151.5; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}$ 368.0645; found 368.0641.

5-Bromo-*N*-methyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1i). According to the procedure described for the preparation of **1a**, 5-bromo-2-iodo-*N*-methylaniline (**S2i**) (256 mg, 0.819 mmol) was converted into **1i** (216 mg, 71%) by the reaction with **S5a** (166 mg, 0.901 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (28.8 mg, 0.0410 mmol), CuI (7.80 mg, 0.0410 mmol) and Et_3N (0.36 mL) in DMF (2.7 mL) at room temperature for 10 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}): 3407 (NH); ^1H NMR (500 MHz, CDCl_3) δ :

1
2
3
4
5
6 2.80 (t, $J = 6.6$ Hz, 2H), 2.85 (d, $J = 5.2$ Hz, 3H), 3.81 (t, $J = 6.6$ Hz, 2H), 4.46 (s, 2H), 4.78-4.83
7 (br m, 1H), 6.66 (d, $J = 1.7$ Hz, 1H), 6.70 (dd, $J = 8.0, 1.7$ Hz, 1H), 7.07 (d, $J = 8.0$ Hz, 1H), 7.29-
8 7.34 (m, 3H), 7.42-7.46 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.0, 30.1, 59.0, 68.1, 77.6,
9 84.7, 86.5, 93.3, 106.6, 111.6, 118.7, 122.4, 123.6, 128.3 (2C), 128.6, 131.7 (2C), 132.6, 150.9;
10 HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}$ 368.0645; found 368.0643.
11
12
13
14
15
16
17

18 **2-Bromo-*N*-methyl-6-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1j).**

19
20 According to the procedure described for the preparation of **S2h**, 2-bromo-6-iodoaniline (**S1j**) (543
21 mg, 1.82 mmol) was converted into **S2j** (170 mg, <30%) including impurities by the reaction with
22 MeLi (1.09 M in Et_2O ; 2.01 mL, 2.19 mmol) and MeI (147 μL , 2.37 mmol) in THF (6.1 mL) at –
23 78 °C to room temperature for 2.5 h. Column chromatography: silica gel (gradient 1% to 5%
24 EtOAc in hexanes) and amine silica gel (hexane only); According to the procedure described for
25 the preparation of **1a**, **S2j** (142 mg, *ca.* 0.425 mmol) including impurities was converted into **1j**
26 (53.3 mg, *ca.* 32%) by the reaction with **S5a** (92.4 mg, 0.502 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (16.0 mg,
27 0.0228 mmol), CuI (4.34 mg, 0.0228 mmol) and Et_3N (0.20 mL) in DMF (1.5 mL) at room
28 temperature for 9 h. Column chromatography: silica gel (gradient 2% to 5% EtOAc in hexanes
29 and gradient 1% to 3% EtOAc in hexane): yellow oil; IR (neat cm^{-1}): 3418 (NH); ^1H NMR (500
30 MHz, CDCl_3) δ : 2.80 (t, $J = 6.9$ Hz, 2H), 3.16 (s, 3H), 3.81 (t, $J = 6.9$ Hz, 2H), 4.32-4.38 (br m,
31 1H), 4.44 (s, 2H), 6.57 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.25 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.29-7.33 (m, 3H),
32 7.37 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.43-7.46 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.0, 34.6,
33 58.9, 68.0, 79.5, 84.8, 86.4, 91.8, 112.8, 113.3, 119.8, 122.5, 128.3 (2C), 128.5, 131.8 (2C), 132.8,
34 133.5, 148.8; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}$ 368.0645; found 368.0638.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 ***N*-Methyl-2-(4-{[3-(trimethylsilyl)prop-2-yn-1-yl]oxy}but-1-yn-1-yl)aniline (S9).** A mixture
55 of 2-iodo-*N*-methylaniline (**S2a**) (729 mg, 3.11 mmol), [3-(but-3-yn-1-yloxy)prop-1-yn-1-
56
57
58
59
60

1
2
3
4
5
6 yl]trimethylsilane (**S5f**) (618 mg, 3.43 mmol), PdCl₂(PPh₃)₂ (109 mg, 0.156 mmol), CuI (29.7 mg,
7
8 0.156 mmol), and Et₃N (1.36 mL, 9.34 mmol) in DMF (10.4 mL) was stirred at room temperature
9
10 under Ar for 13 h. The mixture was diluted with saturated aqueous NH₄Cl. The resulting mixture
11
12 was extracted with EtOAc twice. The combined organic layer was washed with brine, dried over
13
14 Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography
15
16 on silica gel (gradient 2% to 5% EtOAc in hexane) to give **S9** (294 mg, 33%) as an orange oil: IR
17
18 (neat cm⁻¹): 3410 (NH); ¹H NMR (500 MHz, CDCl₃) δ: 0.19 (s, 9H), 2.78 (t, *J* = 6.9 Hz, 2H), 2.90
19
20 (d, *J* = 5.2 Hz, 3H), 3.74 (t, *J* = 6.9 Hz, 2H), 4.23 (s, 2H), 4.67-6.73 (br m, 1H), 6.56 (d, *J* = 7.7
21
22 Hz, 1H), 6.60 (dd, *J* = 7.7, 7.7 Hz, 1H), 7.19 (dd, *J* = 7.7, 7.7 Hz, 1H), 7.24 (d, *J* = 7.7 Hz, 1H);
23
24 ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: -0.27 (3C), 20.8, 30.2, 58.9, 68.2, 78.3, 91.5, 92.1, 101.1,
25
26 107.6, 108.6, 115.8, 129.3, 131.6, 149.9; HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for
27
28 C₁₇H₂₄NNaOSi 308.1441; found 308.1434.
29
30
31
32
33

34 ***N*-Methyl-2-[4-(prop-2-yn-1-yloxy)but-1-yn-1-yl]aniline (S10)**. To a stirred mixture of **S9**
35
36 (1.07 g, 3.74 mmol) in MeOH (7.5 mL) was added K₂CO₃ (517 mg, 1.07 mmol). After being
37
38 stirred at room temperature for 30 min, the mixture was filtered. The filtrate was evaporated to
39
40 dryness and the residue was purified by column chromatography on silica gel (gradient 2% to 5%
41
42 EtOAc in hexane) to give **S10** (645 mg, 81%) as an orange oil: IR (neat cm⁻¹): 3401 (NH), 2248
43
44 (C≡C); ¹H NMR (500 MHz, CDCl₃) δ: 2.47 (t, *J* = 2.3 Hz, 1H), 2.78 (t, *J* = 6.9 Hz, 2H), 2.89 (d,
45
46 *J* = 5.2 Hz, 3H), 3.75 (t, *J* = 6.9 Hz, 2H), 4.23 (d, *J* = 2.3 Hz, 2H), 4.66-4.72 (br m, 1H), 6.56 (d,
47
48 *J* = 7.7 Hz, 1H), 6.60 (dd, *J* = 7.7, 7.7 Hz, 1H), 7.19 (dd, *J* = 7.7, 7.7 Hz, 1H), 7.24 (d, *J* = 7.7 Hz,
49
50 1H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 20.9, 30.3, 58.2, 68.3, 74.6, 78.3, 79.4, 92.1, 107.6,
51
52 108.7, 115.9, 129.4, 131.7, 150.0; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₁₄H₁₆NO 214.1226;
53
54 found 214.1222.
55
56
57
58
59
60

2-(4-{[3-(4-Chlorophenyl)prop-2-yn-1-yl]oxy}but-1-yn-1-yl)-*N*-methylaniline (1k).

According to the procedure described for the preparation of **1a**, **S10** (127 mg, 0.595 mmol) was converted into **1k** (138 mg, 71%) by the reaction with 1-chloro-4-iodobenzene (156 mg, 0.655 mmol), PdCl₂(PPh₃)₂ (20.9 mg, 0.0298 mmol), CuI (5.67 mg, 0.0298 mmol) and Et₃N (0.26 mL) in DMF (1.9 mL) at room temperature for 7 h. Column chromatography: silica gel (gradient 2% to 10% EtOAc in hexane and hexane/acetone = 20/1): yellow oil; IR (neat cm⁻¹): 3410 (NH); ¹H NMR (500 MHz, CDCl₃) δ: 2.80 (t, *J* = 6.9 Hz, 2H), 2.85 (s, 3H), 3.79 (t, *J* = 6.9 Hz, 2H), 4.43 (s, 2H), 4.67-4.74 (br m, 1H), 6.52-6.56 (m, 1H), 6.56-6.61 (m, 1H), 7.16-7.20 (m, 1H), 7.22-7.28 (m, 3H), 7.34-7.38 (m, 2H); ¹³C {¹H} NMR (125 MHz, CDCl₃) δ: 20.9, 30.2, 58.8, 68.4, 78.4, 85.2, 85.8, 92.1, 107.6, 108.7, 115.9, 120.9, 128.6 (2C), 129.4, 131.7, 132.9 (2C), 134.5, 150.0; HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₂₀H₁₈ClNNaO 346.0969; found 346.0966.

2-(4-{[3-(4-Bromophenyl)prop-2-yn-1-yl]oxy}but-1-yn-1-yl)-*N*-methylaniline (1l).

According to the procedure described for the preparation of **1a**, **S10** (101 mg, 0.475 mmol) was converted into **1l** (110 mg, 63%) by the reaction with 1-bromo-4-iodobenzene (148 mg, 0.523 mmol), PdCl₂(PPh₃)₂ (16.7 mg, 0.0238 mmol), CuI (4.53 mg, 0.0238 mmol) and Et₃N (0.21 mL) in DMF (1.6 mL) at room temperature for 3 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm⁻¹): 3405 (NH); ¹H NMR (500 MHz, CDCl₃) δ: 2.81 (t, *J* = 6.9 Hz, 2H), 2.87 (d, *J* = 5.2 Hz, 3H), 3.80 (t, *J* = 6.9 Hz, 2H), 4.44 (s, 2H), 4.68-4.73 (br m, 1H), 6.55 (d, *J* = 8.6 Hz, 1H), 6.60 (dd, *J* = 8.6, 8.6 Hz, 1H), 7.19 (dd, *J* = 8.6, 8.6 Hz, 1H), 7.24 (d, *J* = 8.6 Hz, 1H), 7.30 (d, *J* = 8.3 Hz, 2H), 7.44 (d, *J* = 8.3 Hz, 2H); ¹³C {¹H} NMR (125 MHz, CDCl₃) δ: 21.0, 30.3, 58.9, 68.4, 78.4, 85.3, 86.0, 92.1, 107.6, 108.7, 115.9, 121.4, 122.8, 129.4, 131.6 (2C), 131.7, 133.2 (2C), 150.0; HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₂₀H₁₈BrNNaO 390.0464; found 390.0466.

4-[3-({4-[2-(Methylamino)phenyl]but-3-yn-1-yl}oxy)prop-1-yn-1-yl]benzotrile (1m).

According to the procedure described for the preparation of **1a**, **S10** (103 mg, 0.482 mmol) was converted into **1m** (127 mg, 84%) by the reaction with 4-iodobenzotrile (121 mg, 0.530 mmol), PdCl₂(PPh₃)₂ (16.9 mg, 0.0241 mmol), CuI (4.59 mg, 0.0241 mmol) and Et₃N (0.21 mL) in DMF (1.6 mL) at room temperature for 9 h. Column chromatography: silica gel (gradient 6% to 25% EtOAc in hexane): orange oil; IR (neat cm⁻¹): 3416 (NH), 2227 (C≡N); ¹H NMR (500 MHz, CDCl₃) δ: 2.82 (t, *J* = 6.9 Hz, 2H), 2.87 (d, *J* = 5.2 Hz, 3H), 3.81 (t, *J* = 6.9 Hz, 2H), 4.47 (s, 2H), 4.66-4.71 (br m, 1H), 6.56 (d, *J* = 8.0 Hz, 1H), 6.60 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.19 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.24 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 8.6 Hz, 2H), 7.59 (d, *J* = 8.6 Hz, 2H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 21.0, 30.3, 58.8, 68.6, 78.5, 84.8, 89.4, 92.0, 107.6, 108.9, 111.9, 116.0, 118.3, 127.4, 129.5, 131.8, 132.0 (2C), 132.2 (2C), 150.0; HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₂₁H₁₈N₂ONa 337.1311; found 337.1314.

N-Methyl-2-(4-{{3-(*p*-tolyl)prop-2-yn-1-yl}oxy}but-1-yn-1-yl)aniline (1n). According to the procedure described for the preparation of **1a**, **S10** (106 mg, 0.497 mmol) was converted into **1n** (120 mg, 80%) by the reaction with 1-iodo-4-methylbenzene (119 mg, 0.546 mmol), PdCl₂(PPh₃)₂ (17.4 mg, 0.0248 mmol), CuI (4.73 mg, 0.0248 mmol) and Et₃N (0.22 mL) in DMF (1.7 mL) at room temperature for 9 h. Column chromatography: silica gel (gradient 1% to 5% EtOAc in hexane): yellow oil; IR (neat cm⁻¹): 3412 (NH); ¹H NMR (500 MHz, CDCl₃) δ: 2.35 (s, 3H), 2.81 (t, *J* = 6.9 Hz, 2H), 2.87 (s, 3H), 3.81 (t, *J* = 6.9 Hz, 2H), 4.45 (s, 2H), 4.70-4.74 (br m, 1H), 6.55 (d, *J* = 8.0 Hz, 1H), 6.59 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 2H), 7.18 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.24 (d, *J* = 8.0 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 2H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 21.0, 21.5, 30.3, 59.0, 68.3, 78.4, 84.0, 86.6, 92.2, 107.7, 108.7, 115.9, 119.4, 129.0 (2C), 129.4,

1
2
3
4
5
6 131.6 (2C), 131.7, 138.6, 150.0; HRMS (ESI-TOF) m/z : $[M + Na]^+$ calcd for $C_{21}H_{21}NNaO$
7
8 326.1515, found 326.1519.
9

10
11 **2-(4-{[3-(4-Methoxyphenyl)prop-2-yn-1-yl]oxy}but-1-yn-1-yl)-*N*-methylaniline (1o).**
12

13 According to the procedure described for the preparation of **1a**, **S10** (125 mg, 0.587 mmol) was
14 converted into **1o** (63.3 mg, 34%) by the reaction with 1-iodo-4-methoxybenzene (137 mg, 0.587
15 mmol), $PdCl_2(PPh_3)_2$ (20.6 mg, 0.0293 mmol), CuI (5.59 mg, 0.0293 mmol) and Et_3N (0.26 mL)
16 in DMF (2.0 mL) at 60 °C for 3 h. Column chromatography: silica gel (gradient 4% to 20% EtOAc
17 in hexane): orange oil; IR (neat cm^{-1}): 3411 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 2.81 (t, $J = 6.6$
18 Hz, 2H), 2.87 (d, $J = 4.0$ Hz, 3H), 3.79-3.83 (m, 5H), 4.44 (s, 2H), 4.70-4.74 (br m, 1H), 6.55 (d,
19 $J = 7.4$ Hz, 1H), 6.59 (dd, $J = 7.4, 7.4$ Hz, 1H), 6.83 (d, $J = 8.6$ Hz, 2H), 7.18 (dd, $J = 7.4, 7.4$ Hz,
20 1H), 7.24 (d, $J = 7.4$ Hz, 1H), 7.39 (d, $J = 8.6$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 21.0,
21 30.3, 55.3, 59.0, 68.2, 78.4, 83.4, 86.4, 92.2, 107.7, 108.7, 113.9 (2C), 114.5, 115.9, 129.4, 131.7,
22 133.2 (2C), 150.0, 160.0; HRMS (ESI-TOF) m/z : $[M + Na]^+$ calcd for $C_{21}H_{21}NNaO_2$ 342.1465;
23 found 342.1474.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **2-(4-{[3-(3-Chlorophenyl)prop-2-yn-1-yl]oxy}but-1-yn-1-yl)-*N*-methylaniline (1p).**
40

41 According to the procedure described for the preparation of **1a**, **S10** (186 mg, 0.873 mmol) was
42 converted into **1p** (219 mg, 78%) by the reaction with 1-chloro-3-iodobenzene (208 mg, 0.873
43 mmol), $PdCl_2(PPh_3)_2$ (30.6 mg, 0.0436 mmol), CuI (8.31 mg, 0.0436 mmol) and Et_3N (0.38 mL)
44 in DMF (2.9 mL) at room temperature for 4 h. Column chromatography: silica gel (gradient 4%
45 to 15% EtOAc in hexane): yellow oil; IR (neat cm^{-1}): 3425 (NH); 1H NMR (500 MHz, $CDCl_3$) δ :
46 2.80 (t, $J = 6.9$ Hz, 2H), 2.86 (d, $J = 2.9$ Hz, 3H), 3.79 (t, $J = 6.9$ Hz, 2H), 4.43 (s, 2H), 4.68-4.73
47 (br m, 1H), 6.54 (d, $J = 8.0$ Hz, 1H), 6.59 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.16-7.20 (m, 1H), 7.20-7.23
48 (m, 1H), 7.23-7.26 (m, 1H), 7.27-7.33 (m, 2H), 7.43 (s, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ :
49
50
51
52
53
54
55
56
57
58
59
60

20.9, 30.2, 58.8, 68.4, 78.4, 84.9, 86.1, 92.1, 107.6, 108.7, 115.9, 124.1, 128.7, 129.4, 129.5, 129.8, 131.5, 131.7, 134.0, 149.9; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{20}H_{19}ClNO$ 324.1150; found 324.1153.

2-(4-{{3-(2-Chlorophenyl)prop-2-yn-1-yl}oxy}but-1-yn-1-yl)-*N*-methylaniline (1q).

According to the procedure described for the preparation of **1a**, **S10** (187 mg, 0.879 mmol) was converted into **1q** (186 mg, 65%) by the reaction with 1-chloro-2-iodobenzene (210 mg, 0.879 mmol), $PdCl_2(PPh_3)_2$ (30.8 mg, 0.0439 mmol), CuI (8.37 mg, 0.0439 mmol) and Et_3N (0.38 mL) in DMF (2.9 mL) at room temperature for 4 h. Column chromatography: silica gel (gradient 4% to 15% EtOAc in hexane): yellow oil; IR (neat cm^{-1}): 3410 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 2.83 (t, $J = 6.9$ Hz, 2H), 2.87 (d, $J = 5.2$ Hz, 3H), 3.86 (t, $J = 6.9$ Hz, 2H), 4.52 (s, 2H), 4.68-4.74 (br m, 1H), 6.55 (d, $J = 8.0$ Hz, 1H), 6.59 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.16-7.22 (m, 2H), 7.23-7.28 (m, 2H), 7.38-7.41 (m, 1H), 7.46-7.50 (m, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 21.0, 30.3, 58.9, 68.3, 78.4, 83.2, 90.1, 92.2, 107.7, 108.7, 115.9, 122.4, 126.4, 129.2, 129.4, 129.5, 131.7, 133.5, 135.9, 150.0; HRMS (ESI-TOF) m/z : $[M + Na]^+$ calcd for $C_{20}H_{18}ClNNaO$ 346.0969; found 346.0971.

***N*-Methyl-2-(4-{{3-(naphthalen-2-yl)prop-2-yn-1-yl}oxy}but-1-yn-1-yl)aniline (1r).**

According to the procedure described for the preparation of **1a**, **S10** (125 mg, 0.588 mmol) was converted into **1r** (80.6 mg, 40%) by the reaction with 2-bromonaphthalene (134 mg, 0.647 mmol), $PdCl_2(PPh_3)_2$ (20.6 mg, 0.0294 mmol), CuI (5.60 mg, 0.0294 mmol) and Et_3N (0.26 mL) in DMF (2.0 mL) at room temperature for 1.5 h and 60 °C for 4.5 h. Column chromatography: silica gel (gradient 4% to 15% EtOAc in hexane): yellow oil; IR (neat cm^{-1}): 3416 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 2.83 (t, $J = 6.9$ Hz, 2H), 2.86 (d, $J = 4.0$ Hz, 3H), 3.85 (t, $J = 6.9$ Hz, 2H), 4.50 (s, 2H), 4.71-4.76 (br m, 1H), 6.54 (d, $J = 8.0$ Hz, 1H), 6.59 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.18 (dd, J

1
2
3
4
5
6 = 8.0, 8.0 Hz, 1H), 7.26 (d, $J = 8.0$ Hz, 1H), 7.46-7.50 (m, 3H), 7.73-7.81 (m, 3H), 7.97 (s, 1H);
7
8 $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.0, 30.2, 59.0, 68.4, 78.4, 85.1, 86.8, 92.2, 107.7, 108.7,
9
10 115.9, 119.7, 126.5, 126.7, 127.7 (2C), 128.0, 128.3, 129.4, 131.7 (2C), 132.8 (2C), 150.0; HRMS
11
12 (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{22}\text{NO}$ 340.1696; found 340.1698.

13
14
15
16 **2-[4-(But-2-yn-1-yloxy)but-1-yn-1-yl]-*N*-methylaniline (1s).** According to the procedure
17
18 described for the preparation of **1a**, **S2a** (427 mg, 1.83 mmol) was converted into **1s** (179 mg,
19
20 43%) by the reaction with 4-(but-2-yn-1-yloxy)but-1-yne (**S5g**) (246 mg, 2.01 mmol),
21
22 $\text{PdCl}_2(\text{PPh}_3)_2$ (64.3 mg, 0.0915 mmol), CuI (17.4 mg, 0.0915 mmol) and Et_3N (0.80 mL) in DMF
23
24 (6.1 mL) at room temperature for 24 h. Column chromatography: silica gel (hexane/acetone =
25
26 20/1): yellow oil; IR (neat cm^{-1}): 3406 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 1.87 (t, $J = 2.3$ Hz,
27
28 3H), 2.77 (t, $J = 6.9$ Hz, 2H), 2.90 (d, $J = 5.2$ Hz, 3H), 3.72 (t, $J = 6.9$ Hz, 2H), 4.18 (q, $J = 2.3$ Hz,
29
30 2H), 4.68-4.73 (br m, 1H), 6.56 (d, $J = 8.0$ Hz, 1H), 6.59 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.19 (dd, $J =$
31
32 8.0, 8.0 Hz, 1H), 7.24 (d, $J = 8.0$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 3.58, 20.9, 30.2,
33
34 58.7, 68.1, 74.8, 78.3, 82.7, 92.2, 107.7, 108.7, 115.8, 129.3, 131.7, 150.0; HRMS (ESI-TOF) m/z :
35
36 $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{18}\text{NO}$ 228.1383; found 228.1388.

37
38
39
40
41 **2-{4-[(3-Phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1t).** According to the procedure
42
43 described for the preparation of **1a**, 2-iodoaniline (424 mg, 1.93 mmol) was converted into **1t** (196
44
45 mg, 37%) by the reaction with **S5a** (384 mg, 2.13 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (67.9 mg, 0.0967 mmol),
46
47 CuI (18.4 mg, 0.0967 mmol) and Et_3N (0.85 mL) in DMF (6.5 mL) at room temperature for 6 h.
48
49 Column chromatography: silica gel (hexane/acetone = 10/1): orange oil; IR (neat cm^{-1}): 3472 (NH),
50
51 3478 (NH); ^1H NMR (500 MHz, CDCl_3) δ : 2.81 (t, $J = 6.9$ Hz, 2H), 3.82 (t, $J = 6.9$ Hz, 2H), 4.21
52
53 (s, 2H), 4.45 (s, 2H), 6.63-6.67 (m, 2H), 7.08 (dd, $J = 7.7, 7.7$ Hz, 1H), 7.24 (d, $J = 7.7$ Hz, 1H),
54
55 7.28-7.34 (m, 3H), 7.43-7.47 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 20.9, 58.9, 68.3, 78.3,
56
57
58
59
60

84.8, 86.4, 91.9, 108.3, 114.1, 117.7, 122.5, 128.3 (2C), 128.5, 129.1, 131.8 (2C), 131.9, 147.9;
HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{19}H_{18}NO$ 276.1383; found 276.1373.

***N*-Benzyl-2-{4-[(3-phenylprop-2-yn-1-yl)oxy]but-1-yn-1-yl}aniline (1u).** According to the procedure described for the preparation of **1a**, *N*-benzyl-2-iodoaniline (**S2k**) (198 mg, 0.641 mmol) was converted into **1u** (176 mg, 75%) by the reaction with **S5a** (127 mg, 0.705 mmol), $PdCl_2(PPh_3)_2$ (22.5 mg, 0.0320 mmol), CuI (6.10 mg, 0.0320 mmol) and Et_3N (0.28 mL) in DMF (2.1 mL) at room temperature for 7 h. Column chromatography: silica gel (gradient 1% to 10% EtOAc in hexane): yellow oil; IR (neat cm^{-1}): 3405 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 2.80 (t, $J = 6.9$ Hz, 2H), 3.78 (t, $J = 6.9$ Hz, 2H), 4.34 (s, 2H), 4.41 (d, $J = 5.7$ Hz, 2H), 5.15-5.19 (br m, 1H), 6.51 (d, $J = 8.0$ Hz, 1H), 6.59 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.10 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.22-7.38 (m, 9H), 7.41 (dd, $J = 7.7, 1.4$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 21.0, 47.6, 58.9, 68.2, 78.4, 84.8, 86.4, 92.5, 107.9, 109.7, 116.3, 122.4, 127.1 (3C), 128.3 (2C), 128.5, 128.6 (2C), 129.3, 131.7 (2C), 131.8, 139.3, 148.9; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{26}H_{24}NO$ 366.1852; found 366.1854.

***N*-Methyl-2-{3-[(3-phenylprop-2-yn-1-yl)oxy]prop-1-yn-1-yl}aniline (1v).** According to the procedure described for the preparation of **1a**, **S2a** (190 mg, 0.817 mmol) was converted into **1v** (136 mg, 61%) by the reaction with [3-(prop-2-yn-1-yloxy)prop-1-yn-1-yl]benzene (**S5b**) (153 mg, 0.899 mmol), $PdCl_2(PPh_3)_2$ (28.7 mg, 0.0408 mmol), CuI (7.78 mg, 0.0408 mmol) and Et_3N (0.36 mL) in DMF (2.7 mL) at room temperature for 6 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}): 3419 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 2.88 (d, $J = 5.2$ Hz, 3H), 4.55 (s, 2H), 4.61 (s, 2H), 4.63-4.66 (br m, 1H), 6.58 (d, $J = 8.0$ Hz, 1H), 6.62 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.24 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.29-7.35 (m, 4H), 7.44-7.48 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 30.2, 57.3, 57.6, 83.7, 84.3, 86.8, 89.9, 106.3, 108.9,

1
2
3
4
5
6 116.0, 122.4, 128.3 (2C), 128.6, 130.3, 131.8 (2C), 132.5, 150.1; HRMS (ESI-TOF) m/z : $[M + H]^+$
7
8 calcd for $C_{19}H_{18}NO$ 276.1383; found 276.1375.
9

10
11 ***N*-Methyl-2-{5-[(3-phenylprop-2-yn-1-yl)oxy]pent-1-yn-1-yl}aniline (1w)**. According to the
12 procedure described for the preparation of **1a**, **S2a** (148 mg, 0.634 mmol) was converted into **1w**
13 (104 mg, 54%) by the reaction with **S5c** (138 mg, 0.698 mmol), $PdCl_2(PPh_3)_2$ (22.3 mg, 0.0317
14 mmol), CuI (6.04 mg, 0.0317 mmol) and Et_3N (0.28 mL) in DMF (2.1 mL) at room temperature
15 for 19 h. Column chromatography: silica gel (hexane/acetone = 20/1): yellow oil; IR (neat cm^{-1}):
16 3422 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 1.95 (tt, $J = 6.9, 6.9$ Hz, 2H), 2.62 (t, $J = 6.9$ Hz, 2H),
17 2.86 (d, $J = 4.6$ Hz, 3H), 3.75 (t, $J = 6.9$ Hz, 2H), 4.40 (s, 2H), 4.58-5.64 (br m, 1H), 6.55 (d, $J =$
18 8.0 Hz, 1H), 6.58 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.18 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.23 (d, $J = 8.0$ Hz, 1H),
19 7.26-7.33 (m, 3H), 7.41-7.45 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 16.6, 28.9, 30.3, 58.9,
20 68.7, 77.4, 85.1, 86.2, 95.0, 108.1, 108.7, 116.0, 122.5, 128.2 (2C), 128.4, 129.2, 131.7 (2C), 131.9,
21 149.7; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{21}H_{22}NO$ 304.1696; found 304.1697.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **4-Methyl-*N*-{4-[2-(methylamino)phenyl]but-3-yn-1-yl}-*N*-(3-phenylprop-2-yn-1-**
38 **yl)benzenesulfonamide (1x)**. According to the procedure described for the preparation of **1a**, **S2a**
39 (144 mg, 0.619 mmol) was converted into **1x** (111 mg, 41%) by the reaction with **S5d** (230 mg,
40 0.681 mmol), $PdCl_2(PPh_3)_2$ (16.7 mg, 0.0237 mmol), CuI (4.52 mg, 0.0237 mmol) and Et_3N (0.21
41 mL) in DMF (1.6 mL) at room temperature for 5.5 h. Column chromatography: silica gel (gradient
42 2% to 5% EtOAc in hexane): yellow oil; IR (neat cm^{-1}): 3408 (NH), 1346 (S=O), 1161 (S=O); 1H
43 NMR (500 MHz, $CDCl_3$) δ : 2.34 (s, 3H), 2.84 (t, $J = 6.9$ Hz, 2H), 2.89 (s, 3H), 3.53 (t, $J = 6.9$ Hz,
44 2H), 4.45 (s, 2H), 4.82-4.87 (br m, 1H), 6.54-6.60 (m, 2H), 7.07 (d, $J = 8.0$ Hz, 2H), 7.19 (dd, $J =$
45 8.0, 8.0 Hz, 1H), 7.21-7.30 (m, 6H), 7.80 (d, $J = 8.0$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$)
46 δ : 19.9, 21.4, 30.1, 37.7, 45.6, 79.3, 81.6, 85.8, 91.5, 107.3, 108.8, 115.7, 122.0, 127.7 (2C), 128.1
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(2C), 128.5, 129.6 (3C), 131.5 (2C), 131.8, 135.8, 143.6, 150.1; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{27}H_{27}N_2O_2S$ 443.1788; found 443.1778.

(S)-2-{4-[(4-Phenylbut-3-yn-2-yl)oxy]but-1-yn-1-yl}aniline (S11). According to the procedure described for the preparation of **1a**, 2-iodoaniline (253 mg, 1.16 mmol) was converted into **S11** (163 mg, 49%) by the reaction with **S5e** (252 mg, 1.27 mmol), $PdCl_2(PPh_3)_2$ (40.6 mg, 0.0578 mmol), CuI (11.0 mg, 0.0578 mmol) and Et_3N (0.50 mL) in DMF (3.9 mL) at room temperature for 9 h. Column chromatography: silica gel (gradient 4% to 10% EtOAc in hexane): yellow oil; $[\alpha]^{25}_D -120.3$ (c 0.67, $CHCl_3$); IR (neat cm^{-1}): 3364 (NH), 3474 (NH); 1H NMR (500 MHz, $CDCl_3$) δ : 1.55 (d, $J = 6.3$ Hz, 3H), 2.80 (t, $J = 6.9$ Hz, 2H), 3.71 (dt, $J = 9.2, 6.9$ Hz, 1H), 3.99 (dt, $J = 9.2, 6.9$ Hz, 1H), 4.21 (s, 2H), 4.48 (q, $J = 6.3$ Hz, 1H), 6.62-6.68 (m, 2H), 7.07 (dd, $J = 7.4, 7.4$ Hz, 1H), 7.23 (d, $J = 7.4$ Hz, 1H), 7.27-7.32 (m, 3H), 7.42-7.46 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 21.1, 22.2, 65.9, 67.1, 78.2, 85.1, 88.8, 92.2, 108.4, 114.0, 117.7, 122.6, 128.2 (2C), 128.3, 129.0, 131.7 (2C), 131.8, 147.9; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{20}H_{20}NO$ 290.1539; found 290.1539.

(S)-N-Methyl-2-{4-[(4-phenylbut-3-yn-2-yl)oxy]but-1-yn-1-yl}aniline (1y). To a stirred solution of **S11** (156 mg, 0.539 mmol) in THF (0.90 mL) was added MeLi (1.1 M in Et_2O ; 0.79 mL, 0.863 mmol) at -78 °C under argon. After the mixture was stirred for 1 h at this temperature, MeI (50.4 μ L, 0.809 mmol) was added to the mixture. The mixture was gradually warmed to room temperature and stirred for 5 h at this temperature. The reaction was quenched with saturated aqueous NH_4Cl . The resulting mixture was extracted with EtOAc twice. The combined organic layer was washed with brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (gradient 2% to 5% EtOAc in hexane) to

1
2
3
4
5
6 give **1y** (39.5 mg, 24%) as a colorless oil; $[\alpha]_D^{25} -105.6$ (*c* 0.59, CHCl₃); IR (neat cm⁻¹): 3400
7
8 (NH); ¹H NMR (500 MHz, CDCl₃) δ: 1.56 (d, *J* = 6.3 Hz, 3H), 2.80 (t, *J* = 6.9 Hz, 2H), 2.87 (s,
9
10 3H), 3.71 (dt, *J* = 9.2, 6.9 Hz, 1H), 3.99 (dt, *J* = 9.2, 6.9 Hz, 1H), 4.49 (q, *J* = 6.3 Hz, 1H), 4.70-
11
12 4.74 (br m, 1H), 6.55 (d, *J* = 8.0 Hz, 1H), 6.59 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.18 (dd, *J* = 8.0, 8.0 Hz,
13
14 1H), 7.24 (d, *J* = 8.0 Hz, 1H), 7.27-7.32 (m, 3H), 7.41-7.46 (m, 2H); ¹³C{¹H} NMR (125 MHz,
15
16 CDCl₃) δ: 21.1, 22.2, 30.2, 65.9, 67.1, 78.2, 85.1, 88.8, 92.5, 107.8, 108.7, 115.9, 122.6, 128.3
17
18 (2C), 128.4, 129.4, 131.7 (3C), 150.0; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₁H₂₂NO
19
20 304.1696; found 304.1695.
21
22
23
24

25 3. Gold-Catalyzed Cascade Cyclization

26
27
28 **(Z)-11-Methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2a) and 4-Methyl-1-**
29
30 **phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3a).** **Condition A:** To a stirred
31
32 mixture of **1a** (303 mg, 1.05 mmol) in EtOH (10 mL) was added 5 mol % IPrAuNTf₂ (45.3 mg,
33
34 0.0523 mmol) at room temperature. After being stirred for 10 min at 60 °C, the reaction mixture
35
36 was filtered through a short pad of celite and silica gel, and the filtrate was evaporated in vacuo to
37
38 give a crude product, which was purified by column chromatography on amine silica gel
39
40 (hexane/EtOAc = 25/1 to 0/100) to give **2a** (258 mg, 85%) and **3a** (22.5 mg, 7%). **Condition B:**
41
42 To a stirred mixture of **1a** (309 mg, 1.07 mmol) in *i*-PrOH (11 mL) was added 5 mol %
43
44 JohnPhosAuNTf₂ (41.4 mg, 0.0533 mmol) at room temperature. After being stirred for 5 min at
45
46 80 °C, the reaction mixture was filtered through a short pad of celite and silica gel, and the filtrate
47
48 was evaporated in vacuo to give a crude product, which was purified by column chromatography
49
50 on amine silica gel (hexane/EtOAc = 30/1 to 10/1) to give **2a** (24.7 mg, 8%) and **3a** (251 mg, 81%).
51
52
53
54
55 Compound **2a**: pale yellow solid; mp 183-186 °C; ¹H NMR (500 MHz, CDCl₃) δ: 2.83-2.94 (br m,
56
57 1H), 3.22-3.35 (br m, 2H), 3.46-3.56 (br m, 1H), 3.79 (s, 3H), 4.12-4.18 (br m, 1H), 4.44-4.51 (br
58
59
60

1
2
3
4
5
6 m, 1H), 6.28 (dd, $J = 8.3, 8.3$ Hz, 1H), 6.80 (d, $J = 8.0$ Hz, 1H), 6.89 (dd, $J = 8.0, 8.0$ Hz, 1H),
7
8 7.16 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.28-7.34 (m, 4H), 7.39-7.44 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz,
9 CDCl_3) δ : 28.4, 29.8, 63.3, 67.8, 109.0, 111.3, 119.5, 120.3, 121.3, 122.4, 126.6, 127.8, 128.0 (2C),
10 128.2 (2C), 137.1, 138.8, 140.9, 141.0; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{NO}$
11 290.1539; found 290.1539. Compound **3a**: ^1H NMR (500 MHz, CDCl_3) δ : 2.02-2.07 (m, 1H),
12 2.31-2.36 (m, 1H), 2.67 (dd, $J = 17.8, 2.6$ Hz, 1H), 2.72 (dd, $J = 17.8, 2.6$ Hz, 1H), 2.86 (s, 3H),
13 3.81-3.86 (m, 1H), 4.02-4.06 (m, 1H), 6.09 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.36 (d, $J = 7.4$ Hz, 1H), 6.46
14 (dd, $J = 7.4, 7.4$ Hz, 1H), 7.08-7.12 (m, 2H), 7.28-7.31 (m, 1H), 7.34-7.37 (m, 2H), 7.83-7.84 (m,
15 2H). The ^1H NMR spectra were in good agreement with those reported.⁹

16
17
18
19
20
21
22
23
24
25
26
27 **(Z)-8-Fluoro-11-methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2b) and 7-**
28
29 **Fluoro-4-methyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3b).** According
30 to the procedure described for **Condition A**, **1b** (56.1 mg, 0.192 mmol) was converted into **2b**
31 (40.1 mg, 68%) and **3b** (1.6 mg, 3%) by the reaction with IPrAuNTf_2 (8.34 mg, 0.00962 mmol) in
32 EtOH (1.9 mL) at 60 °C for 40 min. Column chromatography: amine silica gel (gradient 2% to 5%
33 EtOAc in hexane). According to the procedure described for **Condition B**, **1b** (66.1 mg, 0.215
34 mmol) was converted into **2b** (14.8 mg, 22%) and **3b** (44.0 mg, 67%) by the reaction with
35 IPrAuNTf_2 (8.34 mg, 0.0108 mmol) in *i*-PrOH (2.2 mL) at 80 °C for 10 min. Column
36 chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane). Compound **2b**: pale
37 yellow solid; mp 167-170 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.83-2.93 (br m, 1H), 3.18-3.34 (br
38 m, 2H), 3.45-3.54 (br m, 1H), 3.77 (s, 3H), 4.10-4.19 (br m, 1H), 4.43-4.52 (br m, 1H), 6.25 (dd,
39 $J = 8.0, 8.0$ Hz, 1H), 6.43 (dd, $J = 9.0, 2.3$ Hz, 1H), 6.88 (ddd, $J = 9.0, 9.0, 2.3$ Hz, 1H), 7.21 (dd,
40 $J = 9.0, 4.3$ Hz, 1H), 7.28-7.33 (m, 3H), 7.36-7.40 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ :
41 28.6, 30.0, 63.4, 67.8, 105.3 (d, $J_{\text{C-F}} = 22.8$ Hz), 109.5 (2C), 111.4 (d, $J_{\text{C-F}} = 4.8$ Hz), 122.7, 126.9
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(d, J_{C-F} = 10.8 Hz), 127.9 (2C), 128.0, 128.3 (2C), 133.6, 140.3, 140.5, 140.6, 157.9 (d, J_{C-F} = 235.1 Hz); HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{20}H_{19}FNO$ 308.1445; found 308.1436.

Compound **3b**: yellow oil; 1H NMR (500 MHz, $CDCl_3$) δ : 2.00-2.07 (m, 1H), 2.29-2.35 (m, 1H), 2.67 (dd, J = 17.5, 2.6 Hz, 1H), 2.73 (dd, J = 17.5, 2.6 Hz, 1H), 2.84 (s, 3H), 3.83-3.89 (m, 1H), 4.02-4.07 (m, 1H), 6.12 (dd, J = 2.9, 2.9 Hz, 1H), 6.23-6.27 (m, 1H), 6.78-6.83 (m, 2H), 7.29-7.33 (m, 1H), 7.35-7.39 (m, 2H), 7.78-7.81 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 30.3, 38.6, 40.6, 68.0, 85.6, 103.8, 105.8 (d, J_{C-F} = 8.4 Hz), 112.2 (d, J_{C-F} = 24.0 Hz), 115.8 (d, J_{C-F} = 22.8 Hz), 127.1 (2C), 127.9, 128.2 (d, J_{C-F} = 9.6 Hz), 128.4 (2C), 129.3, 134.4, 142.6, 148.3, 155.6 (d, J_{C-F} = 230.3 Hz); HRMS (ESI-TOF) m/z : $[M + Na]^+$ calcd for $C_{20}H_{18}FNNaO$ 330.1265; found 330.1259.

(Z)-8-Chloro-11-methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2c) and 7-Chloro-4-methyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3c). According to the procedure described for **Condition A**, **1c** (53.2 mg, 0.164 mmol) was converted into **2c** (34.2 mg, 64%) and **3c** (trace) by the reaction with $IPrAuNTf_2$ (7.12 mg, 0.00821 mmol) in EtOH (1.6 mL) at 60 °C for 25 min. Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane). According to the procedure described for **Condition B**, **1c** (49.8 mg, 0.154 mmol) was converted into **2c** (6.6 mg, 13%) and **3c** (39.5 mg, 79%) by the reaction with JohnPhosAuNTf₂ (5.96 mg, 0.00769 mmol) in *i*-PrOH (1.5 mL) at 80 °C for 20 min. Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane). Compound **2c**: white solid; mp 176-179 °C; 1H NMR (500 MHz, $CDCl_3$) δ : 2.81-2.93 (br m, 1H), 3.18-3.32 (br m, 2H), 3.40-3.52 (br m, 1H), 3.76 (s, 3H), 4.09-4.18 (br m, 1H), 4.45-4.47 (br m, 1H), 6.27 (dd, J = 8.0, 8.0 Hz, 1H), 6.75 (d, J = 2.0 Hz, 1H), 7.09 (dd, J = 8.9, 2.0 Hz, 1H), 7.21 (d, J = 8.9 Hz, 1H), 7.29-7.33 (m, 3H), 7.35-7.40 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 28.5, 29.9, 63.4, 67.8, 110.1, 111.0, 119.6, 121.5, 123.0,

1
2
3
4
5
6 125.1, 127.5, 127.8 (2C), 128.0, 128.3 (2C), 135.5, 140.0, 140.2, 140.5; HRMS (ESI-TOF) m/z :
7
8 $[M + H]^+$ calcd for $C_{20}H_{19}ClNO$ 324.1150; found 324.1142. Compound **3c**: yellow oil; 1H NMR
9
10 (500 MHz, $CDCl_3$) δ : 1.99-2.06 (m, 1H), 2.28-2.34 (m, 1H), 2.64-2.74 (m, 2H), 2.83 (s, 3H), 3.78-
11
12 3.85 (m, 1H), 4.00-4.05 (m, 1H), 6.11 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.26 (d, $J = 8.6$ Hz, 1H), 7.00-
13
14 7.06 (m, 2H), 7.29-7.33 (m, 1H), 7.35-7.39 (m, 2H), 7.78-7.82 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz,
15
16 $CDCl_3$) δ : 29.8, 38.6, 40.8, 67.9, 85.5, 103.9, 106.5, 121.1, 124.9, 127.4 (2C), 127.9, 128.4 (2C),
17
18 128.8, 129.2, 129.5, 134.3, 142.5, 150.4; HRMS (ESI-TOF) m/z : $[M + Na]^+$ calcd for
19
20 $C_{20}H_{18}ClNNaO$ 346.0969; found 346.0966.
21
22
23

24
25 **(Z)-8-Bromo-11-methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2d) and 7-**
26
27 **Bromo-4-methyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3d)**. According
28
29 to the procedure described for **Condition A**, **1d** (69.3mg, 0.188mmol) was converted into **2d** (42.9
30
31 mg, 62%) and **3d** (4.1mg, 6%) by the reaction with $IPrAuNTf_2$ (8.16mg, 0.00941mmol) in EtOH
32
33 (1.9 mL) at 60 °C for 20 min. Column chromatography: amine silica gel (hexane/EtOAc = 25/1 to
34
35 15/1). According to the procedure described for **Condition B**, **1d** (60.5 mg, 0.164 mmol) was
36
37 converted into **2d** (6.9 mg, 11%) and **3d** (49.9 mg, 82%) by the reaction with $JohnPhosAuNTf_2$
38
39 (6.37 mg, 0.00822 mmol) in *i*-PrOH (1.6 mL) at 80 °C for 10 min. Column chromatography: amine
40
41 silica gel (gradient 4% to 15% EtOAc in hexane). Compound **2d**: yellow solid; mp 133-138 °C;
42
43 1H NMR (500 MHz, $CDCl_3$) δ : 2.82-2.92 (br m, 1H), 3.19-3.32 (br m, 2H), 3.41-3.51 (br m, 1H),
44
45 3.76-3.78 (br m, 3H), 4.09-4.19 (br m, 1H), 4.42-4.51 (br m, 1H), 6.28 (dd, $J = 8.0, 8.0$ Hz, 1H),
46
47 6.91 (d, $J = 1.7$ Hz, 1H), 7.18 (d, $J = 9.0$ Hz, 1H), 7.23 (dd, $J = 9.0, 1.7$ Hz, 1H), 7.29-7.34 (m,
48
49 3H), 7.36-7.40 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 28.4, 29.9, 63.4, 67.8, 110.5, 111.0,
50
51 112.8, 122.6, 123.1, 124.2, 127.8 (2C), 128.0, 128.2, 128.3 (2C), 135.8, 139.9, 140.1, 140.4;
52
53 HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{20}H_{19}BrNO$ 368.0645; found 368.0647. Compound
54
55
56
57
58
59
60

1
2
3
4
5
6 **3d**: yellow oil; ^1H NMR (500 MHz, CDCl_3) δ : 1.99-2.07 (m, 1H), 2.28-2.35 (m, 1H), 2.65-2.75
7 (m, 2H), 2.84 (s, 3H), 3.78-3.85 (m, 1H), 4.00-4.06 (m, 1H), 6.11 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.23
8 (d, $J = 8.6$ Hz, 1H), 7.14 (d, $J = 1.7$ Hz, 1H), 7.18 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.29-7.34 (m, 1H),
9 7.35-7.40 (m, 2H), 7.78-7.82 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 29.8, 38.6, 40.8, 67.9,
10 85.4, 103.9, 107.1, 108.1, 127.1 (2C), 127.7, 127.9, 128.4 (2C), 129.1, 129.3, 132.4, 134.2, 142.6,
11 150.8; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}$ 368.0645; found 368.0643.
12
13
14
15
16
17
18
19

20 **(Z)-8,11-Dimethyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2e) and 4,7-**
21 **Dimethyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3e).** According to the
22 procedure described for **Condition A**, **1e** (41.5 mg, 0.137 mmol) was converted into **2e** (31.8 mg,
23 77%) and **3e** (1.2 mg, 3%) by the reaction with IPrAuNTf_2 (6.07 mg, 0.00684 mmol) in EtOH (1.4
24 mL) at 60 °C for 20 min. Column chromatography: amine silica gel (gradient 0% to 10% EtOAc
25 in hexane). According to the procedure described for **Condition B**, **1e** (51.4 mg, 0.169 mmol) was
26 converted into **2e** (3.0 mg, 6%) and **3e** (39.5 mg, 77%) by the reaction with JohnPhosAuNTf_2 (6.57
27 mg, 0.00847 mmol) in *i*-PrOH (1.7 mL) at 80 °C for 2 h. Column chromatography: amine silica
28 gel (gradient 4% to 10% EtOAc in hexane). Compound **2e**: white solid; mp 173-175 °C; ^1H NMR
29 (500 MHz, CDCl_3) δ : 2.24 (s, 3H), 2.80-2.89 (br m, 1H), 3.20-3.30 (br m, 2H), 3.43-3.51 (br m,
30 1H), 3.76 (s, 3H), 4.08-4.16 (br m, 1H), 4.42-4.49 (br m, 1H), 6.28 (dd, $J = 8.3, 8.3$ Hz, 1H), 6.60
31 (s, 1H), 6.98 (d, $J = 8.6$ Hz, 1H), 7.21 (d, $J = 8.6$ Hz, 1H), 7.28-7.32 (m, 3H), 7.40-7.44 (m, 2H);
32 $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.4, 28.5, 29.8, 63.4, 67.9, 108.8, 110.7, 119.9, 122.4, 122.8,
33 126.8, 127.7, 127.9 (2C), 128.2 (2C), 128.8, 135.5, 138.9, 140.9 (2C); HRMS (ESI-TOF) m/z : $[\text{M}$
34 $+ \text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{21}\text{NNaO}$ 326.1515; found 326.1508. Compound **3e**: yellow oil; ^1H NMR
35 (500 MHz, CDCl_3) δ : 1.97-2.05 (m, 1H), 2.08 (s, 3H), 2.29-2.35 (m, 1H), 2.61-2.74 (m, 2H), 2.83
36 (s, 3H), 3.82-3.88 (m, 1H), 4.00-4.05 (m, 1H), 6.10 (dd, $J = 2.3, 2.3$ Hz, 1H), 6.30 (d, $J = 8.6$ Hz,
37 58
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 1H), 6.89-6.94 (m, 2H), 7.27-7.32 (m, 1H), 7.34-7.39 (m, 2H), 7.82-7.86 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR
7
8 (125 MHz, CDCl_3) δ : 20.7, 30.1, 38.5, 40.4, 67.9, 85.3, 104.3, 105.9, 125.4, 126.2, 127.3 (2C),
9
10 127.4, 127.6, 128.2 (2C), 128.8, 130.2, 134.7, 143.0, 149.9; HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$
11
12 calcd for $\text{C}_{21}\text{H}_{21}\text{NNaO}$ 326.1515; found 326.1511.
13
14

15
16 **(Z)-8-Methoxy-11-methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2f) and 7-**
17
18 **Methoxy-4-methyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3f).** According
19
20 to the procedure described for **Condition A**, **1f** (50.2 mg, 0.157 mmol) was converted into **2f** (37.4
21
22 mg, 75%) and **3f** (2.6mg, 5%) by the reaction with IPrAuNTf_2 (6.81 mg, 0.00786 mmol) in EtOH
23
24 (1.6 mL) at 60 °C for 15 min. Column chromatography: amine silica gel (gradient 4% to 10%
25
26 EtOAc in hexane) and PTLC (hexane/EtOAc = 3/1). According to the procedure described for
27
28 **Condition B**, **1f** (42.9 mg, 0.134 mmol) was converted into **2f** (6.9 mg, 16%) and **3f** (27.9 mg,
29
30 65%) by the reaction with JohnPhosAuNTf_2 (5.21 mg, 0.00672 mmol) in *i*-PrOH (1.3 mL) at 80 °C
31
32 for 1 h. Column chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane).
33
34 Compound **2f**: white solid; mp 156-158 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.81-2.92 (br m, 1H),
35
36 3.17-3.36 (br m, 2H), 3.49-3.59 (br m, 4H), 3.75 (s, 3H), 4.09-4.20 (br m, 1H), 4.43-4.53 (br m,
37
38 1H), 6.22 (d, $J = 2.3$ Hz, 1H), 6.25 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.80 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.19
39
40 (d, $J = 8.6$ Hz, 1H), 7.27-7.32 (m, 3H), 7.40-7.44 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ :
41
42 28.6, 29.9, 55.6, 63.4, 67.9, 102.5, 109.6, 111.0 (2C), 122.1, 126.9, 127.8, 128.0 (2C), 128.2 (2C),
43
44 132.3, 139.3, 140.8, 141.0, 153.8; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_2$
45
46 320.1645; found 320.1645. Compound **3f**: brown solid; mp 91-93 °C; ^1H NMR (500 MHz, CDCl_3)
47
48 δ : 1.98-2.05 (m, 1H), 2.28-2.34 (m, 1H), 2.64 (dd, $J = 17.5, 2.6$ Hz, 1H), 2.72 (dd, $J = 17.5, 2.6$
49
50 Hz, 1H), 2.82 (s, 3H), 3.56 (s, 3H), 3.85-3.90 (m, 1H), 4.01-4.07 (m, 1H), 6.11 (dd, $J = 2.6, 2.6$
51
52 Hz, 1H), 6.31 (d, $J = 8.0$ Hz, 1H), 6.70 (dd, $J = 8.0, 2.9$ Hz, 1H), 6.74 (d, $J = 2.9$ Hz, 1H), 7.25-
53
54
55
56
57
58
59
60

1
2
3
4
5
6 7.30 (m, 1H), 7.32-7.37 (m, 2H), 7.79-7.83 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 30.5,
7
8 38.4, 40.3, 55.9, 68.1, 85.5, 104.1, 106.4, 111.8, 115.1, 127.3 (2C), 127.7, 128.3 (3C), 129.1, 134.7,
9
10 142.9, 146.6, 152.0; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_2$ 320.1645; found
11
12 320.1635.
13
14

15
16 **(Z)-11-Methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole-8-carbonitrile (2g).**
17

18 According to the procedure described for **Condition A**, **1g** (46.2 mg, 0.147 mmol) was converted
19
20 into **2g** (8.0 mg, 17%) by the reaction with IPrAuNTf_2 (6.37 mg, 0.00735 mmol) in EtOH (1.5
21
22 mL) at 60 °C for 6.5 h, and additional 11.5 h after addition of a second portion of IPrAuNTf_2 (6.37
23
24 mg, 0.00735 mmol). Column chromatography: amine silica gel (gradient 6% to 50% EtOAc in
25
26 hexane) and PTLC (toluene/EtOAc = 5/1). According to the procedure described for **Condition B**,
27
28 **1g** (48.6 mg, 0.155 mmol) was converted into **2g** (2.4 mg, 5%) by the reaction with
29
30 JohnPhosAuNTf₂ (5.99 mg, 0.00773 mmol) in *i*-PrOH (1.5 mL) at 80 °C for 6 h. Column
31
32 chromatography: amine silica gel (gradient 6% to 20% EtOAc in hexane) and PTLC
33
34 (toluene/EtOAc = 5/1). Compound **2g**: yellow solid; mp 230-234 °C; IR (neat cm^{-1}): 2220 ($\text{C}\equiv\text{N}$)
35
36 ^1H NMR (500 MHz, CDCl_3) δ : 2.86-2.98 (br m, 1H), 3.21-3.38 (br m, 2H), 3.43-3.55 (br m, 1H),
37
38 3.83 (s, 3H), 4.13-4.20 (br m, 1H), 4.44-4.53 (br m, 1H), 6.30 (dd, $J = 7.7, 7.7$ Hz, 1H), 7.12 (s,
39
40 1H), 7.31-7.41 (m, 7H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 28.4, 30.1, 63.2, 67.8, 102.5, 109.9,
41
42 112.4, 120.7, 123.8, 124.5, 125.6, 126.4, 127.7 (2C), 128.3, 128.5 (2C), 138.7, 139.5, 140.3, 140.8;
43
44 HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}$ 315.1492; found 315.1494.
45
46
47
48
49

50
51 **8-Bromo-4-methyl-1-phenyl-3*H*,4*H*-8b,3a-(epoxyethano)cyclopenta[*b*]indole (3h).** The
52
53 reaction of **1h** (28.3 mg, 0.768 mmol) with IPrAuNTf_2 (3.33 mg, 0.00384 mmol) in EtOH (0.77
54
55 mL) under **condition A** gave a mixture of unidentified products without producing **2h/3h**.
56
57 According to the procedure described for **Condition B**, **1h** (26.6 mg, 0.0722 mmol) was converted
58
59
60

1
2
3
4
5
6 into **3h** (10.9 mg, 44%) by the reaction with JohnPhosAuNTf₂ (2.80 mg, 0.00361 mmol) in *i*-PrOH
7
8 (0.72 mL) at 80 °C for 5 h. PTLC (hexane/acetone = 5/1). Compound **3h**: yellow solid; mp 174-
9
10 176 °C; ¹H NMR (500 MHz, CDCl₃) δ: 2.08-2.14 (m, 1H), 2.22-2.28 (m, 1H), 2.63 (dd, *J* = 17.2,
11
12 2.3 Hz, 1H), 2.75 (dd, *J* = 17.2, 2.3 Hz, 1H), 2.87 (s, 3H), 3.93-3.99 (m, 1H), 4.07-4.13 (m, 1H),
13
14 5.81 (dd, *J* = 2.6, 2.6 Hz, 1H), 6.31 (d, *J* = 8.0 Hz, 1H), 6.64 (d, *J* = 8.0 Hz, 1H), 6.93 (dd, *J* = 8.0,
15
16 8.0 Hz, 1H), 7.26-7.30 (m, 3H), 7.43-7.46 (m, 2H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 30.1,
17
18 38.0, 41.0, 68.0, 85.9, 104.9, 105.6, 119.8, 121.9, 126.3, 127.2, 127.6 (2C), 129.1 (2C), 130.8,
19
20 132.8, 138.1, 144.0, 153.4; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₀H₁₉BrNO 368.0645;
21
22 found 368.0646.
23
24
25

26
27 **(Z)-9-Bromo-11-methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2i) and 6-**
28
29 **Bromo-4-methyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3i)**. According to
30
31 the procedure described for **Condition A**, **1i** (60.6 mg, 0.165 mmol) was converted into **2i** (38.9
32
33 mg, 64%) and **3i** (11.7 mg, <19%) including inseparable impurities by the reaction with IPrAuNTf₂
34
35 (7.13 mg, 0.00823 mmol) in EtOH (1.7 mL) at 60 °C for 30 min. Column chromatography: amine
36
37 silica gel (gradient 4% to 10% EtOAc in hexane). According to the procedure described for
38
39 **Condition B**, **1i** (55.1 mg, 0.150 mmol) was converted into **2i** (3.4 mg, 6%) and **3i** (43.4 mg, 79%)
40
41 by the reaction with JohnPhosAuNTf₂ (5.80 mg, 0.00748 mmol) in *i*-PrOH (1.5 mL) at 80 °C for
42
43 10 min. Column chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane).
44
45 Compound **2i**: yellow solid; mp 169-172 °C; ¹H NMR (500 MHz, CDCl₃) δ: 2.82-2.91 (br m, 1H),
46
47 3.19-3.35 (br m, 2H), 3.45-3.54 (br m, 1H), 3.75 (s, 3H), 4.09-4.19 (br m, 1H), 4.42-4.52 (br m,
48
49 1H), 6.27 (dd, *J* = 8.0, 8.0 Hz, 1H), 6.63 (d, *J* = 8.3 Hz, 1H), 6.97 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.27-
50
51 7.32 (m, 3H), 7.35-7.39 (m, 2H), 7.46 (d, *J* = 1.7 Hz, 1H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ:
52
53 28.4, 29.9, 63.3, 67.8, 111.5, 112.1, 114.9, 121.5, 122.7, 122.9, 125.4, 127.9 (3C), 128.2 (2C),
54
55
56
57
58
59
60

1
2
3
4
5
6 137.9, 139.3, 140.3, 140.7; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{20}H_{19}BrNO$ 368.0645;
7
8 found 368.0643. Compound **3i**: yellow solid; mp 108-111 °C; 1H NMR (500 MHz, $CDCl_3$) δ : 2.00-
9
10 2.07 (m, 1H), 2.29-2.34 (m, 1H), 2.65-2.74 (m, 2H), 2.84 (s, 3H), 3.78-3.83 (m, 1H), 4.00-4.06 (m,
11
12 1H), 6.08 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.47 (d, $J = 1.7$ Hz, 1H), 6.55 (dd, $J = 8.0, 1.7$ Hz, 1H), 6.89
13
14 (d, $J = 8.0$ Hz, 1H), 7.27-7.32 (m, 1H), 7.33-7.38 (m, 2H), 7.76-7.81 (m, 2H); $^{13}C\{^1H\}$ NMR (125
15
16 MHz, $CDCl_3$) δ : 29.6, 38.8, 41.1, 67.7, 85.4, 103.9, 108.6, 119.4, 123.9, 125.9, 126.3, 127.3 (2C),
17
18 127.8, 128.3 (2C), 129.0, 134.4, 142.6, 152.9; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for
19
20 $C_{20}H_{19}BrNO$ 368.0645; found 368.0642.
21
22
23

24
25 **(Z)-10-Bromo-11-methyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2j) and 5-**
26
27 **Bromo-4-methyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3j)**. According to
28
29 the procedure described for **Condition A**, **1j** (27.3 mg, 0.0742 mmol) was converted into **2j** (19.3
30
31 mg, 71%) and **3j** (trace) by the reaction with $IPrAuNTf_2$ (3.22 mg, 0.00371 mmol) in EtOH (0.74
32
33 mL) at 60 °C for 30 min. Column chromatography: amine silica gel (hexane/EtOAc = 25/1) and
34
35 amine PTLC (hexane/EtOAc = 10/1 \times 2). According to the procedure described for **Condition B**,
36
37 **1j** (25.1 mg, 0.0683 mmol) was converted into **2j** (2.4 mg, 9%) and **3j** (30.0 mg, 80%) by the
38
39 reaction with $JohnPhosAuNTf_2$ (2.65 mg, 0.00341 mmol) in *i*-PrOH (0.68 mL) at 80 °C for 30
40
41 min. Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane).
42
43 Compound **2j**: white solid; mp 206-208 °C; 1H NMR (500 MHz, $CDCl_3$) δ : 2.83-2.90 (m, 1H),
44
45 3.23-3.33 (m, 2H), 3.44-3.50 (m, 1H), 4.11-4.16 (m, 1H), 4.19 (s, 3H), 4.43-4.49 (m, 1H), 6.30
46
47 (dd, $J = 8.6, 6.9$ Hz, 1H), 6.66-6.74 (m, 2H), 7.26-7.32 (m, 4H), 7.34-7.39 (m, 2H); $^{13}C\{^1H\}$ NMR
48
49 (125 MHz, $CDCl_3$) δ : 28.3, 32.6, 63.5, 67.8, 103.5, 112.0, 119.7, 120.6, 123.6, 126.9, 127.8 (2C),
50
51 127.9, 128.3 (2C), 129.6, 133.5, 140.0, 140.6, 140.7; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for
52
53 $C_{20}H_{19}BrNO$ 368.0645; found 368.0648. Compound **3j**: colorless oil; 1H NMR (500 MHz, $CDCl_3$)
54
55
56
57
58
59
60

1
2
3
4
5
6 δ : 2.03-2.10 (m, 1H), 2.37-2.43 (m, 1H), 2.71 (dd, $J = 17.5, 2.6$ Hz, 1H), 2.80 (dd, $J = 17.5, 2.6$
7 Hz, 1H), 3.31 (s, 3H), 3.82-3.88 (m, 1H), 4.00-4.05 (m, 1H), 6.07 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.30
8 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.97 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.20 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.28-7.32
9 (m, 1H), 7.33-7.37 (m, 2H), 7.77-7.80 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 33.2, 39.4,
10 41.6, 67.5, 86.0, 100.0, 102.8, 118.4, 124.0, 127.4 (2C), 127.8, 128.3 (2C), 129.4, 130.7, 134.8,
11 135.2, 142.9, 147.7; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}$ 368.0645; found
12 368.0640.
13
14
15
16
17
18
19
20
21

22
23 **(Z)-6-(4-Chlorophenyl)-11-methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2k) and 1-(4-**
24 **Chlorophenyl)-4-methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3k).** According to
25 the procedure described for **Condition A**, **1k** (37.8 mg, 0.117 mmol) was converted into **2k** (27.6
26 mg, 73%) and **3k** (3.6 mg, <10%) including inseparable impurities by the reaction with IPrAuNTf_2
27 (5.07 mg, 0.00585 mmol) in EtOH (1.2 mL) at 60 °C for 30 min. Column chromatography: amine
28 silica gel (gradient 4% to 15% EtOAc in hexane). According to the procedure described for
29 **Condition B**, **1k** (37.7 mg, 0.117 mmol) was converted into **2k** (2.9 mg, 8%) and **3k** (29.0 mg,
30 77%) by the reaction with JohnPhosAuNTf_2 (4.53 mg, 0.00584 mmol) in *i*-PrOH (1.2 mL) at 80 °C
31 for 30 min. Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane) and
32 **2k** was purified by PTLC (hexane/EtOAc = 5/1). Compound **2k**: yellow solid; mp 178-180 °C; ^1H
33 NMR (500 MHz, CDCl_3) δ : 2.81-2.89 (m, 1H), 3.23-3.32 (m, 2H), 3.45-3.52 (m, 1H), 3.78 (s, 3H),
34 4.10-4.17 (m, 1H), 4.43-4.50 (m, 1H), 6.25 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.80 (d, $J = 7.7$ Hz, 1H), 6.92
35 (dd, $J = 7.7, 7.7$ Hz, 1H), 7.17 (dd, $J = 7.7, 7.7$ Hz, 1H), 7.24-7.28 (m, 2H), 7.30-7.36 (m, 3H);
36 $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 28.4, 29.8, 63.4, 67.8, 109.1, 110.8, 119.6, 120.2, 121.4,
37 122.8, 126.3, 128.4 (2C), 129.2 (2C), 133.6, 137.1, 138.9, 139.5, 139.8; HRMS (ESI-TOF) m/z :
38 $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{ClNO}$ 324.1150; found 324.1156. Compound **3k**: yellow solid; mp 168-
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 170 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.00-2.06 (m, 1H), 2.30-2.36 (m, 1H), 2.67 (dd, $J = 17.5$,
7 2.6 Hz, 1H), 2.72 (dd, $J = 17.5$, 2.6 Hz, 1H), 2.86 (s, 3H), 3.79-3.85 (m, 1H), 4.00-4.05 (m, 1H),
8 6.07 (dd, $J = 2.6$, 2.6 Hz, 1H), 6.37 (d, $J = 7.4$ Hz, 1H), 6.48 (dd, $J = 7.4$, 7.4 Hz, 1H), 7.03 (d, $J =$
9 7.4 Hz, 1H), 7.11 (dd, $J = 7.4$, 7.4 Hz, 1H), 7.32 (d, $J = 8.6$ Hz, 2H), 7.76 (d, $J = 8.6$ Hz, 2H);
10 $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 29.7, 38.7, 40.9, 67.9, 85.0, 104.2, 105.8, 116.9, 124.7, 126.9,
11 128.4 (2C), 128.7 (2C), 129.5, 129.9, 133.3, 133.4, 142.0, 151.8; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$
12 calcd for $\text{C}_{20}\text{H}_{19}\text{ClNO}$ 324.1150; found 324.1151.
13
14
15
16
17
18
19
20
21

22
23 **(Z)-6-(4-Bromophenyl)-11-methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2I) and 1-(4-**
24 **Bromophenyl)-4-methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3I).** According to
25 the procedure described for **Condition A**, **1I** (63.9 mg, 0.174 mmol) was converted into **2I** (36.0
26 mg, 56%) and **3I** (9.9 mg, <15%) including inseparable impurities by the reaction with IPrAuNTf_2
27 (7.52 mg, 0.00868 mmol) in EtOH (1.7 mL) at 60 °C for 30 min. Column chromatography: amine
28 silica gel (gradient 4% to 10% EtOAc in hexane). According to the procedure described for
29 **Condition B**, **1I** (38.2 mg, 0.104 mmol) was converted into **2I** (1.4 mg, 4%) and **3I** (26.5 mg, 69%)
30 by the reaction with JohnPhosAuNTf_2 (4.03 mg, 0.00519 mmol) in *i*-PrOH (1.0 mL) at 80 °C for
31 5 min. Column chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Compound **2I**: white solid; mp 182-184 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.80-2.88 (br m, 1H),
3.22-3.31 (br m, 2H), 3.44-3.52 (br m, 1H), 3.78 (s, 3H), 4.10-4.16 (br m, 1H), 4.42-4.49 (br m,
1H), 6.25 (dd, $J = 8.0$, 8.0 Hz, 1H), 6.80 (d, $J = 8.0$ Hz, 1H), 6.92 (dd, $J = 8.0$, 8.0 Hz, 1H), 7.17
(dd, $J = 8.0$, 8.0 Hz, 1H), 7.28 (d, $J = 8.6$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 8.6$ Hz,
2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 28.4, 29.8, 63.4, 67.8, 109.1, 110.7, 119.6, 120.2, 121.4,
121.8, 122.8, 126.3, 129.6 (2C), 131.3 (2C), 137.0, 138.9, 139.8, 139.9; HRMS (ESI-TOF) m/z :
 $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}$ 368.0645; found 368.0641. Compound **3I**: orange solid; mp 169-

1
2
3
4
5
6 172 °C; ¹H NMR (500 MHz, CDCl₃) δ: 2.00-2.06 (m, 1H), 2.30-2.36 (m, 1H), 2.64-2.74 (m, 2H),
7
8 2.86 (s, 3H), 3.80-3.85 (m, 1H), 4.00-4.05 (m, 1H), 6.09 (dd, *J* = 2.6, 2.6 Hz, 1H), 6.37 (d, *J* = 8.0
9
10 Hz, 1H), 6.48 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 7.12 (dd, *J* = 8.0, 8.0 Hz, 1H),
11
12 7.48 (d, *J* = 8.6 Hz, 2H), 7.70 (d, *J* = 8.6 Hz, 2H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 29.7, 38.7,
13
14 40.9, 67.9, 85.0, 104.2, 105.8, 116.9, 121.7, 124.7, 126.9, 129.0 (2C), 129.6, 129.9, 131.3 (2C),
15
16 133.7, 142.0, 151.8; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₀H₁₉BrNO 368.0645; found
17
18 368.0645.
19
20
21

22
23 **(Z)-4-(11-Methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indol-6-yl)benzotrile (2m) and 4-[4-**
24
25 **Methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indol-1-yl]benzotrile (3m).** According to
26
27 the procedure described for **Condition A**, **1m** (36.3 mg, 0.116 mmol) was converted into **2m** (26.6
28
29 mg, 73%) and **3m** (3.9 mg, <11%) including inseparable impurities by the reaction with IPrAuNTf₂
30
31 (5.00 mg, 0.00577 mmol) in EtOH (1.2 mL) at 60 °C for 30 min. Column chromatography: amine
32
33 silica gel (gradient 6% to 10% EtOAc in hexane). According to the procedure described for
34
35 **Condition B**, **1m** (44.3 mg, 0.141 mmol) was converted into **2m** (2.8 mg, 6%) and **3o** (33.0 mg,
36
37 74%) by the reaction with JohnPhosAuNTf₂ (5.46 mg, 0.00704 mmol) in *i*-PrOH (1.4 mL) at 80 °C
38
39 for 10 min. Column chromatography: amine silica gel (gradient 6% to 20% EtOAc in hexane).
40
41
42
43 Compound **2m**: white solid; IR (neat cm⁻¹): 2226 (C≡N); mp 186-188 °C; ¹H NMR (500 MHz,
44
45 CDCl₃) δ: 2.79-2.90 (br m, 1H), 3.23-3.36 (br m, 2H), 3.47-3.59 (br m, 1H), 3.80 (s, 3H), 4.10-
46
47 4.19 (br m, 1H), 4.44-4.54 (br m, 1H), 6.33 (dd, *J* = 8.0, 8.0 Hz, 1H), 6.72 (d, *J* = 8.0 Hz, 1H),
48
49 6.92 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.18 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 1H), 7.50 (d, *J* =
50
51 8.6 Hz, 2H), 7.58 (d, *J* = 8.6 Hz, 2H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 28.3, 29.8, 63.5, 67.6,
52
53 109.3, 110.1, 111.2, 119.0, 119.8 (2C), 121.6, 125.2, 126.0, 128.5 (2C), 132.1 (2C), 137.1, 139.2,
54
55 139.4, 145.6; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₁H₁₉N₂O 315.1492; found 315.1491.
56
57
58
59
60

1
2
3
4
5
6 Compound **3m**: white solid; IR (neat cm^{-1}): 2245 ($\text{C}\equiv\text{N}$); mp 161-165 °C; ^1H NMR (500 MHz,
7 CDCl_3) δ : 2.01-2.07 (m, 1H), 2.32-2.38 (m, 1H), 2.72 (dd, $J = 18.0, 2.6$ Hz, 1H), 2.78 (dd, $J =$
8 18.0, 2.6 Hz, 1H), 2.87 (s, 3H), 3.81-3.87 (m, 1H), 4.00-4.06 (m, 1H), 6.23 (dd, $J = 2.6, 2.6$ Hz,
9 1H), 6.39 (d, $J = 7.7$ Hz, 1H), 6.49 (dd, $J = 7.7, 7.7$ Hz, 1H), 6.98 (d, $J = 7.7$ Hz, 1H), 7.13 (dd, J
10 = 7.7, 7.7 Hz, 1H), 7.64 (d, $J = 8.6$ Hz, 2H), 7.93 (d, $J = 8.6$ Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz,
11 CDCl_3) δ : 29.7, 38.6, 41.1, 68.0, 85.1, 104.1, 106.0, 111.0, 116.9, 119.1, 124.5, 126.6, 127.8 (2C),
12 130.1, 132.1 (2C), 132.4, 139.4, 141.8, 151.8; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for
13 $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}$ 315.1492; found 315.1495.
14
15
16
17
18
19
20
21
22
23
24

25 **(Z)-11-Methyl-6-(p-tolyl)-1,2,4,11-tetrahydrooxocino[4,5-b]indole (2n) and 4-Methyl-1-(p-**
26 **tolyl)-3H,4H-8b,3a-(epoxyethano)cyclopenta[b]indole (3n)**. According to the procedure
27 described for **Condition A**, **1n** (60.0 mg, 0.198 mmol) was converted into **2n** (31.5 mg, 53%) and
28 **3n** (7.2 mg, 12%) by the reaction with IPrAuNTf_2 (8.57 mg, 0.00989 mmol) in EtOH (2.0 mL) at
29 60 °C for 1 h, and additional 1 h after addition of a second portion of IPrAuNTf_2 (8.57 mg, 0.00989
30 mmol). Column chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane).
31 According to the procedure described for **Condition B**, **1n** (45.1 mg, 0.149 mmol) was converted
32 into **2n** (4.3 mg, 10%) and **3n** (34.3 mg, 76%) by the reaction with JohnPhosAuNTf_2 (5.76 mg,
33 0.00742 mmol) in *i*-PrOH (1.49 mL) at 80 °C for 5 min. Column chromatography: amine silica gel
34 (gradient 4% to 10% EtOAc in hexane). Compound **2n**: white solid; mp 169-172 °C; ^1H NMR
35 (500 MHz, CDCl_3) δ : 2.35 (s, 3H), 2.82-2.91 (br m, 1H), 3.21-3.32 (br m, 2H), 3.45-3.52 (br m,
36 1H), 3.78 (s, 3H), 4.10-4.18 (br m, 1H), 4.43-4.49 (br m, 1H), 6.25 (dd, $J = 8.3, 8.3$ Hz, 1H), 6.84
37 (d, $J = 8.0$ Hz, 1H), 6.90 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.10 (d, $J = 8.0$ Hz, 2H), 7.15 (dd, $J = 8.0, 8.0$
38 Hz, 1H), 7.29-7.33 (m, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 21.2, 28.4, 29.7, 63.3, 67.9,
39 109.0, 111.4, 119.4, 120.4, 121.2, 121.6, 126.6, 127.8 (2C), 128.9 (2C), 137.0, 137.6, 138.1, 138.7,
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 140.7; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{21}H_{22}NO$ 304.1696; found 304.1694.

7
8 Compound **3n**: colorless oil; 1H NMR (500 MHz, $CDCl_3$) δ : 1.99-2.07 (m, 1H), 2.29-2.38 (m, 4H),
9
10 2.63-2.74 (m, 2H), 2.86 (s, 3H), 3.80-3.86 (m, 1H), 4.00-4.06 (m, 1H), 6.05 (dd, $J = 2.3, 2.3$ Hz,
11
12 1H), 6.36 (d, $J = 8.0$ Hz, 1H), 6.47 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.08-7.13 (m, 2H), 7.17 (d, $J = 8.0$
13
14 Hz, 2H), 7.72 (d, $J = 8.0$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 21.2, 29.7, 38.8, 40.7, 67.8,
15
16 84.9, 104.4, 105.7, 116.8, 124.9, 127.2 (3C), 127.9, 128.9 (2C), 129.7, 131.8, 137.3, 142.8, 151.8;
17
18 HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{21}H_{22}NO$ 304.1696; found 304.1696.
19
20
21

22
23 **(Z)-6-(4-Methoxyphenyl)-11-methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2o) and 1-(4-**
24
25 **Methoxyphenyl)-4-methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3o).** According
26
27 to the procedure described for **Condition A**, **1o** (55.5 mg, 0.174 mmol) was converted into **2o**
28
29 (12.4 mg, 22%) and **3o** (7.8 mg, <14%) including inseparable impurities by the reaction with
30
31 $IPrAuNTf_2$ (7.53 mg, 0.00869 mmol) in EtOH (1.7 mL) at 60 °C for 1 h, and additional 1 h after
32
33 addition of a second portion of $IPrAuNTf_2$ (7.53 mg, 0.00869 mmol). Column chromatography:
34
35 amine silica gel (gradient 4% to 10% EtOAc in hexane). According to the procedure described for
36
37 **Condition B**, **1o** (34.9 mg, 0.109 mmol) was converted into **3o** (23.4 mg, 67%) by the reaction
38
39 with $JohnPhosAuNTf_2$ (4.27 mg, 0.00546 mmol) in *i*-PrOH (1.1 mL) at 80 °C for 5 min. Column
40
41 chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane). Compound **2o**: yellow
42
43 solid; mp 144-146 °C; 1H NMR (500 MHz, $CDCl_3$) δ : 2.83-2.91 (m, 1H), 3.22-3.31 (m, 2H), 3.43-
44
45 3.50 (m, 1H), 3.78 (s, 3H), 3.81 (s, 3H), 4.11-4.17 (m, 1H), 4.42-4.49 (m, 1H), 6.20 (dd, $J = 8.3,$
46
47 8.3 Hz, 1H), 6.81-6.86 (m, 3H), 6.91 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.16 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.32
48
49 (d, $J = 8.0$ Hz, 1H), 7.35 (d, $J = 9.2$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 28.5, 29.8, 55.2,
50
51 63.3, 67.9, 109.0, 111.4, 113.5 (2C), 119.4, 120.4, 120.8, 121.2, 126.6, 129.1 (2C), 133.6, 137.0,
52
53 138.7, 140.3, 159.4; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{21}H_{22}NO_2$ 320.1645; found
54
55
56
57
58
59
60

1
2
3
4
5
6 320.1642. Compound **3o**: yellow oil; ^1H NMR (500 MHz, CDCl_3) δ : 1.99-2.06 (m, 1H), 2.30-2.36
7 (m, 1H), 2.63-2.72 (m, 2H), 2.85 (s, 3H), 3.79-3.85 (m, 4H), 4.01-4.05 (m, 1H), 5.98 (dd, $J = 2.6$,
8 2.6 Hz, 1H), 6.36 (d, $J = 8.0$ Hz, 1H), 6.47 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.87-6.91 (m, 2H), 7.08-7.12
9 (m, 2H), 7.77 (d, $J = 8.6$ Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 29.7, 38.8, 40.6, 55.2, 67.8,
10 84.9, 104.4, 105.7, 113.6 (2C), 116.8, 124.8, 126.9, 127.2, 127.4, 128.6 (2C), 129.7, 142.5, 151.9,
11 159.2; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_2$ 320.1645; found 320.1641.
12
13
14
15
16
17
18
19

20
21 **(Z)-6-(3-Chlorophenyl)-11-methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2p) and 1-(3-**
22 **Chlorophenyl)-4-methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3p).** According to
23 the procedure described for **Condition A**, **1p** (43.8 mg, 0.136 mmol) was converted into **2p** (31.1
24 mg, 71%) and **3p** (2.9 mg, <7%) including inseparable impurities by the reaction with IPrAuNTf_2
25 (5.88 mg, 0.00678 mmol) in EtOH (1.4 mL) at 60 °C for 1 h. Column chromatography: amine
26 silica gel (gradient 4% to 10% EtOAc in hexane). According to the procedure described for
27 **Condition B**, **1p** (47.9 mg, 0.148 mmol) was converted into **2p** (3.8 mg, 8%) and **3p** (35.6 mg,
28 74%) by the reaction with JohnPhosAuNTf_2 (5.75 mg, 0.00742 mmol) in *i*-PrOH (1.5 mL) at 80 °C
29 for 1 h. Column chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane).
30
31 Compound **2p**: yellow solid; mp 171-174 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.80-2.90 (br m, 1H),
32 3.22-3.33 (br m, 2H), 3.44-3.53 (br m, 1H), 3.78 (s, 3H), 4.10-4.18 (br m, 1H), 4.42-4.51 (br m,
33 1H), 6.25 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.81 (d, $J = 8.0$ Hz, 1H), 6.92 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.17
34 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.19-7.23 (m, 1H), 7.25-7.28 (m, 2H), 7.32 (d, $J = 8.0$ Hz, 1H), 7.40-
35 7.43 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 28.4, 29.8, 63.4, 67.7, 109.1, 110.7, 119.7,
36 120.1, 121.4, 123.5, 126.3 (2C), 127.8 (2C), 129.4, 134.1, 137.1, 138.9, 139.8, 143.1; HRMS (ESI-
37 TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{ClNO}$ 324.1150; found 324.1146. Compound **3p**: yellow oil;
38 ^1H NMR (500 MHz, CDCl_3) δ : 2.00-2.06 (m, 1H), 2.30-2.36 (m, 1H), 2.68 (dd, $J = 17.8, 2.9$ Hz,
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 1H), 2.73 (dd, $J = 17.8, 2.9$ Hz, 1H), 2.86 (s, 3H), 3.80-3.86 (m, 1H), 4.00-4.05 (m, 1H), 6.11 (dd,
7
8 $J = 2.9, 2.9$ Hz, 1H), 6.37 (d, $J = 8.0$ Hz, 1H), 6.49 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.05 (d, $J = 8.0$ Hz,
9
10 1H), 7.12 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.25-7.31 (m, 2H), 7.71-7.74 (m, 1H), 7.79-7.82 (m, 1H);
11
12 $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 29.7, 38.7, 40.9, 67.8, 85.0, 104.2, 105.8, 116.9, 124.7, 125.5,
13
14 126.8, 127.4, 127.7, 129.5, 129.9, 130.3, 134.2, 136.7, 141.9, 151.8; HRMS (ESI-TOF) m/z : $[\text{M} +$
15
16 $\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{ClNO}$ 324.1150; found 324.1148.
17
18
19

20
21 **(E)-6-(2-Chlorophenyl)-11-methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2q) and 1-(2-**
22
23 **Chlorophenyl)-4-methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3q).** According to
24
25 the procedure described for **Condition A**, **1q** (47.2 mg, 0.146 mmol) was converted into **2q** (33.2
26
27 mg, 70%) and **3q** (5.7 mg, <12%) including inseparable impurities by the reaction with IPrAuNTf_2
28
29 (6.34 mg, 0.00731 mmol) in EtOH (1.5 mL) at 60 °C for 1h. Column chromatography: amine silica
30
31 gel (gradient 4% to 15% EtOAc in hexane). According to the procedure described for **Condition**
32
33 **B**, **1q** (40.9 mg, 0.127 mmol) was converted into **2q** (11.1 mg, 27%) and **3q** (10.8 mg, 26%) by
34
35 the reaction with JohnPhosAuNTf_2 (4.91 mg, 0.00633 mmol) in *i*-PrOH (1.3 mL) at 80 °C for 3 h.
36
37 Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane). Compound **2q**:
38
39 white solid; mp 149-151 °C; ^1H NMR (500 MHz, $\text{DMSO-}d_6$, 100 °C) δ : 3.12-3.16 (br m, 2H),
40
41 3.70-3.76 (m, 5H), 4.00-4.04 (br m, 2H), 5.83 (dd, $J = 7.2, 7.2$ Hz, 1H), 6.62 (d, $J = 8.0$ Hz, 1H),
42
43 6.74 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.01 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.29-7.37 (m, 4H), 7.42 (dd, $J = 8.0,$
44
45 1.7 Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 28.5, 29.8, 63.2, 67.4, 109.0, 111.5, 119.3, 119.6,
46
47 121.2, 125.6, 126.2, 126.5, 128.6, 129.9, 131.5, 133.5, 136.8, 138.0, 139.6, 141.2; HRMS (ESI-
48
49 TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{ClNO}$ 324.1150; found 324.1149. Compound **3q**: yellow oil;
50
51
52 ^1H -NMR (500 MHz, CDCl_3) δ : 2.10-2.16 (m, 1H), 2.23-2.30 (m, 1H), 2.67 (dd, $J = 17.8, 2.3$ Hz,
53
54 1H), 2.88-2.94 (m, 4H), 3.84-3.89 (m, 1H), 4.00-4.06 (m, 1H), 6.10 (dd, $J = 2.3, 2.3$ Hz, 1H), 6.38
55
56
57
58
59
60

(d, $J = 8.0$ Hz, 1H), 6.46 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.68 (d, $J = 8.0$ Hz, 1H), 7.11 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.23 (ddd, $J = 7.7, 7.7, 1.7$ Hz, 1H), 7.28 (ddd, $J = 7.7, 7.7, 1.1$ Hz, 1H), 7.39 (dd, $J = 7.7, 1.1$ Hz, 1H), 7.84 (dd, $J = 7.7, 1.7$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 29.8, 38.9, 42.3, 67.3, 84.0, 105.5, 105.8, 116.9, 124.3, 126.1, 127.0, 128.4, 129.6, 129.9, 130.8, 133.7, 134.2, 134.4, 138.4, 151.5; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{19}\text{ClNO}$ 324.1150; found 324.1152.

(Z)-11-Methyl-6-(naphthalen-2-yl)-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2r) and 4-Methyl-1-(naphthalen-2-yl)-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3r). According to the procedure described for **Condition A**, **1r** (32.0 mg, 0.0943 mmol) was converted into **2r** (20.0 mg, 63%) and **3r** (2.8 mg, <9%) including inseparable impurities by the reaction with IPrAuNTf_2 (4.09 mg, 0.00474 mmol) in EtOH (0.9 mL) at 60 °C for 9 h. Column chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexane) and **3r** was purified by PTLC (hexane/acetone = 5/1). According to the procedure described for **Condition B**, **1r** (39.2, mg, mmol) was converted into **3r** (20.2 mg, 52%) by the reaction with JohnPhosAuNTf_2 (4.48 mg, 0.00577 mmol) in *i*-PrOH (1.2 mL) at 80 °C for 5 h. Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane). Compound **2r**: yellow solid; mp 190-193 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.89-2.97 (br m, 1H), 3.26-3.37 (br m, 2H), 3.51-3.60 (br m, 1H), 3.82 (s, 3H), 4.13-4.21 (br m, 1H), 4.49-4.56 (br m, 1H), 6.41 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.77-6.85 (m, 2H), 7.12-7.17 (m, 1H), 7.33 (d, $J = 8.6$ Hz, 1H), 7.40-7.47 (m, 2H), 7.55 (dd, $J = 8.0, 1.7$ Hz, 1H), 7.73-7.78 (m, 2H), 7.80-7.84 (m, 1H), 7.89 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 28.5, 29.8, 63.4, 67.9, 109.0, 111.3, 119.6, 120.4, 121.3, 123.1, 125.8, 125.9, 126.2, 126.6, 127.0, 127.5, 127.7, 128.3, 133.1, 133.4, 137.1, 138.6, 138.9, 140.9; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{21}\text{NO}$ 340.1696; found 340.1699. Compound **3r**: yellow oil; ^1H NMR (500 MHz, CDCl_3) δ :

1
2
3
4
5
6 2.03-2.11 (m, 1H), 2.34-2.40 (m, 1H), 2.73 (dd, $J = 17.5, 2.6$ Hz, 1H), 2.78 (dd, $J = 17.5, 2.6$ Hz,
7 1H), 2.88 (s, 3H), 3.86-3.92 (m, 1H), 4.08-4.13 (m, 1H), 6.24 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.38 (d, J
8 = 8.0 Hz, 1H), 6.42 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.10 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.13 (d, $J = 8.0$ Hz,
9 1H), 7.43-7.50 (m, 2H), 7.78-7.87 (m, 3H), 7.91 (d, $J = 6.9$ Hz, 1H), 8.43 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR
10 (125 MHz, CDCl_3) δ : 29.8, 38.8, 40.8, 68.0, 85.1, 104.5, 105.8, 116.9, 125.0, 125.5, 125.9, 126.0,
11 126.3, 127.2, 127.5, 127.8, 128.5, 129.4, 129.8, 132.1, 132.9, 133.4, 143.1, 151.9; HRMS (ESI-
12 TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{21}\text{NO}$ 340.1696; found 340.1697.
13
14
15
16
17
18
19
20
21

22
23 **(Z)-6,11-Dimethyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2s) and 1,4-Dimethyl-3*H*,4*H*-**
24 **8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3s).** To a stirred mixture of **1s** (31.7 mg, 0.139 mmol)
25 in *i*-PrOH was added MS3Å at room temperature. After the mixture was stirred for 30 min at this
26 temperature, IPrAuNTf₂ (6.04 mg, 0.0697 mmol) was added to the mixture. After being stirred for
27 10 h at 80 °C, the reaction mixture was filtered through a short pad of celite and silica gel, and the
28 filtrate was evaporated in vacuo to give a crude product, which was purified by PTLC
29 (hexane/acetone = 5/1) and PTLC (toluene/EtOAc = 5/1) to give **2s** (5.1 mg, 16%) and **3s** (2.5 mg,
30 8%). According to the procedure described for **Condition B**, **1s** (46.1 mg, 0.203 mmol) was
31 converted into **2s** (2.4 mg, 5%) and **3s** (15.5 mg, 34%) by the reaction with JohnPhosAuNTf₂ (7.86
32 mg, 0.0101 mmol) in *i*-PrOH (2.0 mL) at 80 °C for 30 min. Column chromatography: amine silica
33 gel (gradient 4% to 10% EtOAc in hexane). **Condition C**: To a stirred mixture of **1s** (22.6 mg,
34 0.0994 mmol) in DCE (0.99 mL) was added 5 mol % IPrAuNTf₂ (4.31 mg, 0.0497 mmol) at room
35 temperature. After being stirred for 10 min at 80 °C, the reaction mixture was filtered through a
36 short pad of celite and silica gel, and the filtrate was evaporated in vacuo to give a crude product,
37 which was purified by PTLC (hexane/acetone = 5/1) to give **2s** (trace) and **3s** (18.5 mg, 82%).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Compound **2s**: orange solid; mp 93-95 °C; ^1H NMR (500 MHz, CDCl_3) δ : 2.30 (s, 3H), 2.67-2.86

(br m, 1H), 3.08-3.28 (br m, 2H), 3.29-3.43 (br m, 1H), 3.72 (s, 3H), 4.02-4.16 (br m, 1H), 4.20-4.33 (br m, 1H), 5.85 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.12 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.22 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 1H), 7.62 (d, $J = 8.0$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 23.3, 28.4, 29.7, 63.6, 67.6, 109.2, 113.4, 119.5, 119.7, 121.2, 122.4, 126.1, 136.8, 136.9, 137.3; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{18}\text{NO}$ 228.1383; found 228.1381. Compound **3s**: ^1H NMR (500 MHz, CDCl_3) δ : 1.93 (d, $J = 1.1$ Hz, 3H), 1.94-1.98 (m, 1H), 2.19-2.24 (m, 1H), 2.42-2.46 (m, 1H), 2.58-2.62 (m, 1H), 2.83 (s, 3H), 3.71-3.75 (m, 1H), 3.85-3.89 (m, 1H), 5.42 (m, 1H), 6.36 (dd, $J = 8.0, 1.1$ Hz, 1H), 6.64 (ddd, $J = 7.7, 7.4, 1.1$ Hz, 1H), 7.15 (ddd, $J = 8.0, 7.7, 1.1$ Hz, 1H), 7.29 (dd, $J = 7.4, 1.1$ Hz, 1H). The ^1H NMR spectra were in good agreement with those reported.⁹

(Z)-6-Phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2t) and 1-Phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3t). According to the procedure described for **Condition A**, **1t** (42.0 mg, 0.153 mmol) was converted into **2t** (13.3 mg, 32%) and **3x** (2.8 mg, 7%) by the reaction with IPrAuNTf_2 (6.61 mg, 0.00763 mmol) in EtOH (1.5 mL) at 60 °C for 9 h. Column chromatography: amine silica gel (gradient 4% to 40% EtOAc in hexane) and **3t** was purified by PTLC (hexane/Acetone = 5/1). According to the procedure described for **Condition B**, **1t** (48.4 mg, 0.176 mmol) was converted into **3t** (8.6 mg, 18%) by the reaction with JohnPhosAuNTf_2 (6.82 mg, 0.00879 mmol) in *i*-PrOH (1.8 mL) at 80 °C for 6 h. Column chromatography: amine silica gel (gradient 4% to 15% EtOAc in hexane). Compound **2t**: orange oil; ^1H NMR (500 MHz, $\text{DMSO-}d_6$, 100 °C) δ : 2.94 (t, $J = 4.6$ Hz, 2H), 3.60 (s, 2H), 3.88 (s, 2H), 6.13 (t, $J = 8.0$ Hz, 1H), 6.56 (d, $J = 8.0$ Hz, 1H), 6.73 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.97 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.27-7.34 (m, 6H), 10.95 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 31.4, 63.9, 68.0, 110.5, 111.7, 119.8, 120.4, 121.7, 122.7, 127.7, 127.8, 128.0 (2C), 128.2 (2C), 135.3, 137.3, 140.6, 140.8; HRMS (ESI-

1
2
3
4
5
6 TOF) m/z : $[M + H]^+$ calcd for $C_{19}H_{18}NO$ 276.1383; found 276.1383. Compound **3t**: colorless oil;
7
8 1H NMR (500 MHz, $CDCl_3$) δ : 2.19-2.25 (m, 1H), 2.28-2.33 (m, 1H), 2.72 (dd, $J = 17.5, 2.6$ Hz,
9 1H), 2.93 (dd, $J = 17.5, 2.6$ Hz, 1H), 3.84-3.91 (m, 1H), 4.03-4.08 (m, 1H), 4.14 (s, 1H), 6.09 (dd,
10 $J = 2.6, 2.6$ Hz, 1H), 6.56 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.59 (d, $J = 8.0$ Hz, 1H), 7.06 (dd, $J = 8.0, 8.0$
11 Hz, 1H), 7.12 (d, $J = 8.0$ Hz, 1H), 7.28-7.32 (m, 1H), 7.34-7.39 (m, 2H), 7.84 (d, $J = 7.4$ Hz, 2H);
12
13 $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 43.0, 46.2, 67.7, 80.1, 106.3, 109.7, 118.8, 125.2, 127.4 (2C),
14 127.6, 127.8, 128.2 (2C), 129.3, 129.6, 134.8, 143.0, 151.3; HRMS (ESI-TOF) m/z : $[M + H]^+$
15 calcd for $C_{19}H_{18}NO$ 276.1383; found 276.1380.
16
17
18
19
20
21
22
23
24

25 **(Z)-11-Benzyl-6-methyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2u) and 4-Benzyl-1-**
26 **methyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3u)**. According to the procedure
27 described for **Condition A**, **1u** (52.6 mg, 0.144 mmol) was converted into **2u** (29.6 mg, 56%) and
28 **3u** (trace) by the reaction with $IPrAuNTf_2$ (6.24 mg, 0.00720 mmol) in EtOH (1.4 mL) at 60 °C
29 for 30 min. Column chromatography: amine silica gel (gradient 2% to 5% EtOAc in hexanes) and
30 amine PTLC(hexane/EtOAc = 5/1). According to the procedure described for **Condition B**, **1u**
31 (51.0 mg, 0.140 mmol) was converted into **2u** (4.0 mg, 8%) and **3u** (39.5 mg, 77%) by the reaction
32 with $JohnPhosAuNTf_2$ (5.41 mg, 0.00698 mmol) in *i*-PrOH (1.4 mL) at 80 °C for 10 min. Column
33 chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexanes). Compound **2u**: white
34 solid; mp 150-152 °C; 1H NMR (500 MHz, $CDCl_3$) δ : 2.77-2.87 (br m, 1H), 2.90-2.99 (br m, 1H),
35 3.10-3.19 (br m, 1H), 3.43-3.52 (br m, 1H), 3.88-3.96 (br m, 1H), 4.41-4.50 (br m, 1H), 5.37-5.48
36 (m, 2H), 6.29 (dd, $J = 8.0, 8.0$ Hz, 1H), 6.85 (d, $J = 7.4$ Hz, 1H), 6.91 (t, $J = 7.4$ Hz, 1H), 7.04 (d,
37 $J = 7.4$ Hz, 2H), 7.12 (dd, $J = 7.4, 7.4$ Hz, 1H), 7.26-7.35 (m, 7H), 7.41-7.45 (m, 2H); $^{13}C\{^1H\}$
38 NMR (125 MHz, $CDCl_3$) δ : 28.5, 46.6, 63.2, 67.8, 109.4, 112.0, 119.8, 120.5, 121.7, 122.7, 126.0
39 (2C), 126.7, 127.6, 127.8, 128.0 (2C), 128.2 (2C), 129.0 (2C), 137.0, 137.7, 138.7, 140.6, 141.0;
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{26}H_{24}NO$ 366.1852; found 366.1854. Compound **3u**:
7
8 yellow oil; 1H NMR (500 MHz, $CDCl_3$) δ : 2.02-2.09 (m, 1H), 2.29-2.36 (m, 1H), 2.69-2.79 (m,
9
10 2H), 3.91-3.98 (m, 1H), 4.04-4.09 (m, 1H), 4.42-4.50 (m, 2H), 6.10 (dd, $J = 2.6, 2.6$ Hz, 1H), 6.21
11
12 (d, $J = 8.0$ Hz, 1H), 6.48 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.00 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.12 (d, $J = 8.0$
13
14 Hz, 1H), 7.25-7.40 (m, 8H), 7.86 (d, $J = 7.4$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$) δ : 39.9,
15
16 41.9, 49.2, 67.9, 85.4, 104.6, 106.7, 117.2, 124.9, 126.7 (2C), 127.0, 127.3, 127.4 (2C), 127.7,
17
18 128.2 (2C), 128.6 (3C), 129.7, 134.7, 138.9, 143.2, 151.7; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd
19
20 for $C_{26}H_{24}NO$ 366.1852; found 366.1851.
21
22
23
24

25 **10-Methyl-5-phenyl-3,10-dihydro-1H-oxepino[3,4-b]indole (2v)**. According to the procedure
26
27 described for **Condition A**, **1v** (50.8 mg, 0.184 mmol) was converted into **2v** (31.8 mg, 63%) by
28
29 the reaction with $IPrAuNTf_2$ (8.00 mg, 0.00922 mmol) in EtOH (1.8 mL) at 60 °C 5 h. Column
30
31 chromatography: amine silica gel (gradient 4% to 10% EtOAc in hexanes). According to the
32
33 procedure described for **Condition B**, **1v** (28.8 mg, 0.105 mmol) was converted into **2v** (12.7 mg,
34
35 44%) by the reaction with $JohnPhosAuNTf_2$ (4.06 mg, 0.00523 mmol) in *i*-PrOH (1.0 mL) at 80 °C
36
37 for 9 h. Column chromatography: amine silica gel (gradient 2% to 10% EtOAc in hexanes).
38
39 Compound **2v**: orange oil; 1H NMR (500 MHz, $CDCl_3$) δ : 3.81 (s, 3H), 4.03 (d, $J = 6.9$ Hz, 2H),
40
41 4.80 (s, 2H), 6.31 (t, $J = 6.9$ Hz, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.92 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.21
42
43 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.33-7.38 (m, 4H), 7.42-7.47 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$)
44
45 δ : 29.9, 61.2, 64.4, 109.5, 114.4, 119.7, 121.1, 122.0, 123.4, 125.4, 127.9, 128.2 (2C), 128.3 (2C),
46
47 137.4, 140.0, 140.2, 144.0; HRMS (ESI-TOF) m/z : $[M + H]^+$ calcd for $C_{19}H_{18}NO$ 276.1383; found
48
49 276.1387.
50
51
52
53
54

55 **5-Methyl-10-phenyl-3,4-dihydro-2H,5H-9b,4a-prop[1]enopyrano[3,2-b]indole (3w)**. The
56
57 reaction of **1w** (40.8 mg, 0.134 mmol) with $IPrAuNTf_2$ (5.21 mg, 0.00672 mmol) in EtOH (1.3
58
59
60

1
2
3
4
5
6 mL) under **condition A** gave a mixture of unidentified products without producing **2w/3w**.
7
8 According to the procedure described for **Condition B**, **1w** (40.7 mg, 0.134 mmol) was converted
9
10 into **3w** (11.4 mg, 28%) by the reaction with JohnPhosAuNTf₂ (5.20 mg, 0.00671 mmol) in *i*-
11
12 PrOH (1.3 mL) at 80 °C for 7 h. Column chromatography: amine silica gel (gradient 2% to 5%
13
14 EtOAc in hexane). Compound **3w**: blue oil; ¹H NMR (500 MHz, CDCl₃) δ: 1.50-1.57 (m, 1H),
15
16 1.63-1.70 (m, 1H), 1.77-1.83 (m, 1H), 1.96-2.02 (m, 1H), 2.42 (dd, *J* = 16.9, 2.6 Hz, 1H), 2.46 (dd,
17
18 *J* = 16.9, 2.6 Hz, 1H), 2.77 (s, 3H), 3.58-3.68 (m, 2H), 6.33 (dd, *J* = 2.6, 2.6 Hz, 1H), 6.48 (d, *J* =
19
20 7.4 Hz, 1H), 6.59 (dd, *J* = 7.4, 7.4 Hz, 1H), 7.10-7.15 (m, 2H), 7.24-7.28 (m, 1H), 7.30-7.35 (m,
21
22 2H), 7.80 (d, *J* = 6.9 Hz, 2H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 20.4, 26.4, 29.4, 39.5, 61.0,
23
24 74.3, 93.5, 107.2, 117.8, 124.6, 127.2 (2C), 127.4 (2C), 128.1 (2C), 129.3, 130.0, 135.0, 142.7,
25
26 151.7; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₁H₂₂NO 304.1696; found 304.1698.
27
28
29
30

31 **(Z)-11-Methyl-6-phenyl-3-tosyl-2,3,4,11-tetrahydro-1H-azocino[4,5-*b*]indole (2x).** 32


33 According to the procedure described for **Condition A**, **1x** (49.1 mg, 0.111 mmol) was converted
34
35 into **2x** (30.9 mg, 63%) by the reaction with IPrAuNTf₂ (4.81 mg, 0.00555 mmol) in EtOH (1.1
36
37 mL) at 60 °C 3.5 h. Column chromatography: amine silica gel (gradient 6% to 18% EtOAc in
38
39 hexane). According to the procedure described for **Condition B**, **1x** (48.5 mg, 0.110 mmol) was
40
41 converted into **2x** (32.5 mg, 67%) by the reaction with JohnPhosAuNTf₂ (4.25 mg, 0.00548 mmol)
42
43 in *i*-PrOH (1.1 mL) at 80 °C for 20 min. Column chromatography: amine silica gel (gradient 6%
44
45 to 25% EtOAc in hexane). Compound **2x**: white solid; mp 163-166 °C; IR (neat cm⁻¹): 1333 (S=O),
46
47 1157 (S=O); ¹H NMR (500 MHz, CDCl₃) δ: 2.37 (s, 3H), 2.62-2.70 (br m, 1H), 2.81-2.89 (br m,
48
49 1H), 2.90-2.96 (br m, 1H), 3.27-3.33 (br m, 1H), 3.71 (s, 3H), 4.01-4.08 (br m, 1H), 4.34-4.40 (br
50
51 m, 1H), 6.30 (dd, *J* = 8.0, 8.0 Hz, 1H), 6.79 (d, *J* = 8.0 Hz, 1H), 6.87 (dd, *J* = 8.0, 8.0 Hz, 1H),
52
53 7.13 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.21-7.30 (m, 6H), 7.34-7.38 (m, 2H), 7.67 (d, *J* = 8.0 Hz, 2H);
54
55
56
57
58
59
60

¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 21.4, 26.1, 29.7, 43.1, 47.2, 109.0, 111.4, 119.6, 120.3, 121.5, 121.6, 126.4, 127.0 (2C), 127.7 (2C), 127.8, 128.1 (2C), 129.7 (2C), 136.5, 137.0, 137.2, 140.4 (2C), 143.2; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₇H₂₇N₂O₂S 443.1788; found 443.1787.

2-[1-Methyl-3-(1-phenylpropa-1,2-dien-1-yl)-1H-indol-2-yl]ethan-1-ol (4a). To a stirred mixture of **1a** (19.0 mg, 0.0657 mmol) in *i*-PrOH (0.66 mL) was added 5 mol % JohnPhosAuNTf₂ (2.55 mg, 0.00328 mmol) at room temperature. After being stirred for 5 min at 40 °C, the reaction mixture was filtered through a short pad of celite and silica gel, and the filtrate was evaporated in vacuo to give a crude product, which was purified by PTLC (hexane/acetone = 5/1) to give **4a** (6.6 mg, 35%), **2a** (2.6 mg, 14%) and **3a** (8.8 mg, 46%). Compound **4a**: brown oil; IR (neat cm⁻¹): 3348 (OH), 1933 (C=C=C); ¹H NMR (500 MHz, CDCl₃) δ: 1.48 (t, *J* = 5.4 Hz, 1H), 3.08 (t, *J* = 6.9 Hz, 2H), 3.80 (s, 3H), 3.83 (dt, *J* = 5.4, 6.9 Hz, 2H), 5.19 (s, 2H), 7.01 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.17-7.24 (m, 3H), 7.25-7.29 (m, 2H), 7.30-7.36 (m, 3H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ: 28.5, 30.1, 61.9, 76.7, 101.2, 107.9, 109.0, 119.5, 119.7, 121.4, 126.9, 127.0 (2C), 127.2, 128.3 (2C), 135.2, 136.5, 137.2, 210.1; HRMS (ESI-TOF) *m/z*: [M + H]⁺ calcd for C₂₀H₂₀NO 290.1539; found 290.1530.

(Z)-4,11-Dimethyl-6-phenyl-1,2,4,11-tetrahydrooxocino[4,5-*b*]indole (2y) and 3,4-Dimethyl-1-phenyl-3*H*,4*H*-8*b*,3*a*-(epoxyethano)cyclopenta[*b*]indole (3y). According to the procedure described for **Condition B**, (*S*)-**1y** (14.9 mg, 0.0491 mmol; >99% ee) was converted into **2y** (5.2 mg, 35%; 0% ee) and **3y** (5.2 mg, 35%; 0% ee) by the reaction with IPrAuNTf₂ (2.13 mg, 0.00246 mmol) in EtOH (0.49 mL) at 60 °C for 5 h. PTLC: amine silica gel (hexane/acetone = 5/1) and amine silica gel (hexane/EtOAc = 5/1). Compound **2y**: white solid; mp 164-166 °C; ¹H NMR (500 MHz, CDCl₃) δ: 1.35 (d, *J* = 6.3 Hz, 3H), 2.81-2.88 (m, 1H), 3.25-3.31 (m, 1H), 3.39-3.46 (m, 1H), 3.66-3.74 (m, 1H), 3.78 (s, 3H), 4.20-4.26 (m, 1H), 5.93 (d, *J* = 8.6 Hz, 1H), 6.81

(d, $J = 8.0$ Hz, 1H), 6.89 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.15 (dd, $J = 8.0, 8.0$ Hz, 1H), 7.27-7.32 (m, 4H), 7.39-7.43 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 23.2, 28.8, 29.7, 63.4, 72.9, 109.0, 111.6, 119.4, 120.4, 121.2, 126.6, 127.6, 127.9 (2C), 128.2 (2C), 128.9, 137.0, 138.2, 138.6, 140.9; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}$ 304.1696; found 304.1692. Compound **3y**: yellow oil; ^1H NMR (500 MHz, CDCl_3) δ : 1.27 (d, $J = 7.4$ Hz, 3H), 2.05-2.10 (m, 1H), 2.12-2.18 (m, 1H), 2.85-2.90 (m, 4H), 3.81-3.87 (m, 1H), 4.04-4.08 (m, 1H), 5.99 (d, $J = 2.3$ Hz, 1H), 6.39 (d, $J = 7.4$ Hz, 1H), 6.48 (dd, $J = 7.4, 7.4$ Hz, 1H), 7.09 (d, $J = 7.4$ Hz, 1H), 7.12 (dd, $J = 7.4, 7.4$ Hz, 1H), 7.27-7.32 (m, 1H), 7.33-7.38 (m, 2H), 7.86 (d, $J = 7.4$ Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ : 16.5, 29.8, 32.9, 43.3, 68.7, 87.8, 104.3, 105.9, 116.9, 124.9, 127.3, 127.5 (2C), 127.7, 128.3 (2C), 129.8, 134.4, 134.8, 141.5, 151.7; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}$ 304.1696; found 304.1696. The relative configuration of **3y** was determined by NOE analysis.



2-(1-Methyl-3-(1-phenylbuta-1,2-dien-1-yl)-1*H*-indol-2-yl)ethan-1-ol (4y) To a stirred mixture of (*S*)-**1y** (16.5 mg, 0.0544 mmol; >99% ee) in EtOH (0.54 mL) was added 5 mol % IPrAuNTf₂ (2.36 mg, 0.00272 mmol) at 60 °C. After being stirred for 1 h at 60 °C, the reaction mixture was filtered through a short pad of celite and silica gel, and the filtrate was evaporated in vacuo to give a crude product, which was purified by PTLC (hexane/acetone = 5/1) to give **4y** (6.2 mg, <38%) including inseparable impurities, **2y** (2.7 mg, 16%) and **3y** (2.5 mg, <15%) including inseparable impurities. Compound **4y**: brown oil; IR (neat cm^{-1}): 3397 (OH), 2128 (C=C=C); ^1H

1
2
3
4
5
6 NMR (500 MHz, CDCl₃) δ : 1.84 (d, J = 7.4 Hz, 3H), 3.08 (t, J = 6.9 Hz, 2H), 3.78-3.84 (m, 5H),
7
8 5.58 (q, J = 7.4 Hz, 1H), 7.01 (dd, J = 8.0, 8.0 Hz, 1H), 7.16-7.22 (m, 3H), 7.23-7.27 (m, 2H),
9
10 7.30-7.35 (m, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ : 14.5, 28.5, 30.1, 62.1, 87.3, 100.9, 109.0
11
12 (2C), 119.4, 119.8, 121.3, 126.7, 127.1 (2C), 127.3, 128.2 (2C), 135.0, 137.1, 137.6, 206.6; HRMS
13
14 (ESI-TOF) m/z : [M + H]⁺ calcd for C₂₁H₂₂NO 304.1696; found 304.1697.
15
16
17

18 ASSOCIATED CONTENT

21 Supporting Information.

22
23
24 HPLC chromatograms, NMR spectra and synthetic schemes. The Supporting Information is
25
26 available free of charge on the ACS Publications website at DOI:
27
28
29

30 AUTHOR INFORMATION

32 Corresponding Authors

33
34 * E-mail: hohno@pharm.kyoto-u.ac.jp
35
36

37
38 * E-mail: sinuki@pharm.kyoto-u.ac.jp
39
40

41 ORCID

42
43 Shinsuke Inuki: 0000-0002-7525-1280
44

45 Shinya Oishi: 0000-0002-2833-2539
46

47 Hiroaki Ohno: 0000-0002-3246-4809
48
49

50 Notes

51
52 The authors declare no competing financial interest.
53
54
55

56 ACKNOWLEDGMENTS

57
58
59
60

1
2
3
4
5
6 This work was supported by the JSPS KAKENHI (Grant Numbers JP18H04615, JP18H04408 and
7 JP17H03971), by the Platform Project for Supporting Drug Discovery and Life Science Research
8 (Platform for Drug Discovery, Informatics, and Structural Life Science) from the Japan Agency
9 for Medical Research and Development (AMED), (Grant Numbers JP18gm1010007 and
10 JP18ak0101072), and by the Uehara Memorial Foundation.
11
12
13
14
15
16
17

18 REFERENCES

19
20
21 (1) (a) Somei, M.; Yamada, F. Simple indole alkaloids and those with a non-rearranged
22 monoterpene unit. *Nat. Prod. Rep.* **2005**, *22*, 73-103. (b) Gul, W.; Hamann, M. T. Indole alkaloid
23 marine natural products: An established source of cancer drug leads with considerable promise for
24 the control of parasitic, neurological and other diseases. *Life Sci.* **2005**, *78*, 442-453.
25
26
27
28

29
30 (2) Sravanthi, T.; Manju, S. Indoles-a promising scaffold for drug development. *Eur. J. Pharm.*
31 *Sci.* **2016**, *91*, 1-10.
32
33
34

35
36 (3) (a) Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: Increasing Saturation as an
37 Approach to Improving Clinical Success. *J. Med. Chem.* **2009**, *52*, 6752-6756. (b) Shultz, M. D.
38 Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved
39 Oral Drugs. *J. Med. Chem.* **2019**, *62*, 1701-1714.
40
41
42
43
44

45
46 (4) (a) Wang, M.; Rong, Z.-Q.; Zhao, Y. Stereoselective synthesis of ϵ -lactones or spiro-
47 heterocycles through NHC-catalyzed annulation: divergent reactivity by catalyst control. *Chem.*
48 *Commun.* **2014**, *50*, 15309-15312. (b) Huang, L.; Dai, L.; You, S. Enantioselective Synthesis of
49 Indole-Annulated Medium-Sized Rings. *J. Am. Chem. Soc.* **2016**, *138*, 5793-5796. (c) Wang, Y.;
50 Yang, L.; Rong, Z.; Liu, T.; Liu, R.; Zhao, Y. Pd-Catalyzed Enantioselective [6+4] Cycloaddition
51 of Vinyl Oxetanes with Azadienes to Access Ten-Membered Heterocycles. *Angew. Chem. Int. Ed.*
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **2018**, *57*, 1596-1600.
7
8

9 (5) (a) Dorel, R.; Echavarren, A. M. Gold (I)-Catalyzed Activation of Alkynes for the
10 Construction of Molecular Complexity. *Chem. Rev.* **2015**, *115*, 9028-9072. (b) Hamada, N.;
11 Yoshida, Y.; Oishi, S.; Ohno, H. Gold-Catalyzed Cascade Reaction of Skipped Diynes for the
12 Construction of a Cyclohepta [b] pyrrole Scaffold. *Org. Lett.* **2017**, *19*, 3875-3878. (c) Liu, R.;
13 Wang, Q.; Wei, Y.; Shi, M. Synthesis of indolizine derivatives containing eight-membered rings
14 via a gold-catalyzed two-fold hydroarylation of diynes. *Chem. Commun.* **2018**, *54*, 1225-1228 and
15 references cited therein.
16
17
18
19
20
21
22
23
24

25 (6) (a) Liu, Y.; Xu, W.; Wang, X. Gold (I)-Catalyzed Tandem Cyclization Approach to
26 Tetracyclic Indolines. *Org. Lett.* **2010**, *12*, 1448-1451. (b) Podoll, J. D.; Liu, Y.; Chang, L.; Walls,
27 S.; Wang, W.; Wang, X. Bio-inspired synthesis yields a tricyclic indoline that selectively
28 resensitizes methicillin-resistant *Staphylococcus aureus* (MRSA) to beta-lactam antibiotics. *Proc.*
29 *Natl. Acad. Sci. U. S. A.* **2013**, *110*, 15573-15578. (c) Xu, W.; Wang, W.; Wang, X. Gold-
30 Catalyzed Cyclization Leads to a Bridged Tetracyclic Indolenine that Represses β -Lactam
31 Resistance. *Angew. Chem. Int. Ed.* **2015**, *54*, 9546-9549.
32
33
34
35
36
37
38
39
40
41

42 (7) (a) Ferrer, C.; Echavarren, A. M. Gold-Catalyzed Intramolecular Reaction of Indoles with
43 Alkynes: Facile Formation of Eight-Membered Rings and an Unexpected Allenylation. *Angew.*
44 *Chem. Int. Ed.* **2006**, *45*, 1105-1109. (b) Ferrer, C.; Amijs, C. H.; Echavarren, A. M. Intra-and
45 Intermolecular Reactions of Indoles with Alkynes Catalyzed by Gold. *Chem. Eur. J.* **2007**, *13*,
46 1358-1373. (c) Ferrer, C.; Escribano-Cuesta, A.; Echavarren, A. M. Synthesis of the tetracyclic
47 core skeleton of the lundurines by a gold-catalyzed cyclization. *Tetrahedron* **2009**, *65*, 9015-9020.
48
49
50
51
52
53
54
55
56
57
58
59
60


(8) Hirano, K.; Inaba, Y.; Takahashi, N.; Shimano, M.; Oishi, S.; Fujii, N.; Ohno, H. Direct Synthesis of Fused Indoles by Gold-Catalyzed Cascade Cyclization of Diynes. *J. Org. Chem.* **2011**, *76*, 1212-1227.

(9) Tokimizu, Y.; Oishi, S.; Fujii, N.; Ohno, H. Gold-Catalyzed Cascade Cyclization of 2-Alkynyl-*N*-Propargylanilines by Rearrangement of a Propargyl Group. *Angew. Chem. Int. Ed.* **2015**, *54*, 7862-7866.


(10) The indole immediate resulting from the first cyclization was detected.


(11) Some unidentified side products were observed along with the desired indole **2o**, implying that the product **2o** bearing an electron-rich aryl group, or the reaction intermediates would be unstable under the condition.

(12) The reaction of **1y** under condition B (5 mol % JohnPhosAuNTf₂, 0.1M in *i*PrOH, 80 °C) gave the indole **2y** (<31%, 0% ee).



(13) Isolation of allene **4y** and determination of the enantiomeric excess of **4y**.





(14) (a) Butler, K. L.; Tragni, M.; Widenhoefer, R. A. Gold (I)-Catalyzed Stereoconvergent, Intermolecular Enantioselective Hydroamination of Allenes. *Angew. Chem. Int. Ed.* **2012**, *51*, 5175-5178. (b) Khrakovsky, D. A.; Tao, C.; Johnson, M. W.; Thornbury, R. T.; Shevick, S. L.; Toste, F. D. Enantioselective, stereodivergent hydroazidation and hydroamination of allenenes catalyzed by acyclic diaminocarbene (ADC) gold (I) complexes. *Angew. Chem. Int. Ed.* **2016**, *55*, 6079-6083.

(15) (a) Sherry, B. D.; Toste, F. D. Gold (I)-Catalyzed Propargyl Claisen Rearrangement. *J. Am. Chem. Soc.* **2004**, *126*, 15978-15979. (b) Jin, S.; Jiang, C.; Peng, X.; Shan, C.; Cui, S.; Niu, Y.; Liu, Y.; Lan, Y.; Liu, Y.; Cheng, M. Gold (I)-Catalyzed Angle Strain Controlled Strategy to Furopyran Derivatives from Propargyl Vinyl Ethers: Insight into the Regioselectivity of Cycloisomerization. *Org. Lett.* **2016**, *18*, 680-683. (c) Pertschi, R.; Wagner, P.; Ghosh, N.; Gandon, V.; Blond, G. Gold (I)-Catalyzed Synthesis of Furopyrans: Insight into Hetero-Diels–Alder Reactions. *Org. Lett.* **2019**, *21*, 6084-6088.

(16) Duan, Y.; Liu, Y.; Bi, S.; Ling, B.; Jiang, Y.; Liu, P. Theoretical Study of Gold-Catalyzed Cyclization of 2-Alkynyl-*N*-propargylanilines and Rationalization of Kinetic Experimental Phenomena. *J. Org. Chem.* **2016**, *81*, 9381-9388.

(17) (a) Gorin, D. J.; Sherry, B. D.; Toste, F. D. Ligand Effects in Homogeneous Au Catalysis. *Chem. Rev.* **2008**, *108*, 3351-3378. (b) Gatineau, D.; Goddard, J.; Mouries-Mansuy, V.;

1
2
3
4
5
6 Fensterbank, L. When NHC Ligands Make a Difference in Gold Catalysis. *Isr. J. Chem.* **2013**, *53*,
7
8 892-900.
9

10
11 (18) Liedholm, B. Copper (I)-induced halogen-hydrogen exchange of 2-halogenoanilines. *Acta*
12
13 *Chem. Scand.* **1993**, *47*, 701-701.
14
15

16
17 (19) Shen, H.; Vollhardt, K. P. C. Remarkable Switch in the Regiochemistry of the Iodination of
18
19 Anilines by *N*-Iodosuccinimide: Synthesis of 1, 2-Dichloro-3, 4-diiodobenzene. *Synlett* **2012**, *2012*,
20
21 208-214.
22
23

24
25 (20) Le, C. M.; Sperger, T.; Fu, R.; Hou, X.; Lim, Y. H.; Schoenebeck, F.; Lautens, M.
26
27 Stereoselective synthesis of methylene oxindoles via palladium (II)-catalyzed intramolecular
28
29 cross-coupling of carbamoyl chlorides. *J. Am. Chem. Soc.* **2016**, *138*, 14441-14448.
30
31

32
33 (21) Gao, P.; Yan, X.; Tao, T.; Yang, F.; He, T.; Song, X.; Liu, X.; Liang, Y. Copper-Catalyzed
34
35 Trifluoromethylation–Cyclization of Enynes: Highly Regioselective Construction of
36
37 Trifluoromethylated Carbocycles and Heterocycles. *Chem. Eur. J.* **2013**, *19*, 14420-14424.
38
39

40
41 (22) Scott, S. K.; Grenning, A. J. An Enyne Cope Rearrangement Enables Polycycloalkane
42
43 Synthesis from Readily Available Starting Materials. *Angew. Chem. Int. Ed.* **2017**, *56*, 8125-8129.
44

45
46 (23) Jones, G. B.; Wright, J. M.; Hynd, G.; Wyatt, J. K.; Warner, P. M.; Huber, R. S.; Li, A.;
47
48 Kilgore, M. W.; Sticca, R. P.; Pollenz, R. S. Oxa-enediynes: Probing the electronic and
49
50 stereoelectronic contributions to the Bergman cycloaromatization. *J. Org. Chem.* **2002**, *67*, 5727-
51
52 5732.
53
54
55
56
57
58
59
60

1
2
3
4
5
6 (24) Ye, F.; Boukattaya, F.; Haddad, M.; Ratovelomanana-Vidal, V.; Michelet, V. Synthesis of
7
8 2-aminopyridines via ruthenium-catalyzed [2+2+2] cycloaddition of 1, 6-and 1, 7-diynes with
9
10 cyanamides: scope and limitations. *New J. Chem.* **2018**, *42*, 3222-3235.

11
12
13 (25) Watanabe, K.; Miyazaki, Y.; Okubo, M.; Zhou, B.; Tsuji, H.; Kawatsura, M. Nickel-
14
15 Catalyzed Asymmetric Propargylic Amination of Propargylic Carbonates Bearing an Internal
16
17 Alkyne Group. *Org. Lett.* **2018**, *20*, 5448-5451.

18
19
20 (26) Peng, Q.; Hu, J.; Huo, J.; Yuan, H.; Xu, L.; Pan, X. Cp*Rh(III) catalyzed *ortho*-halogenation
21
22 of *N*-nitrosoanilines by solvent-controlled regioselective C–H functionalization. *Org. Biomol.*
23
24 *Chem.* **2018**, *16*, 4471-4481.

25
26
27 (27) Kulyashova, A. E.; Mikheeva, E. V.; Danilkina, N. A.; Balova, I. A. Synthesis of 2-(buta-1,
28
29 3-diynyl)-*N,N*-dimethylanilines using reductive methylation step. *Mendeleev Commun.* **2014**, *24*,
30
31 102-104.

32
33
34 (28) Kudoh, T.; Mori, T.; Shirahama, M.; Yamada, M.; Ishikawa, T.; Saito, S.; Kobayashi, H.
35
36 Intramolecular Anionic Diels–Alder Reactions of 1-Aryl-4-oxahepta-1, 6-diyne Systems in
37
38 DMSO. *J. Am. Chem. Soc.* **2007**, *129*, 4939-4947.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60